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ABSTRACT OF THE DISSERTATION 
 
ESTROGEN AND LITHIUM: FACILITATING FACTORS INVOLVED IN BRAIN 
CELL SIGNALING PATHWAYS 
by 
James Jason Valdés 
Florida International University, 2009 
Miami, Florida 
Professor Ophelia I. Weeks, Major Professor 
Learning and memory in adult females decline during menopause and estrogen 
replacement therapy is commonly prescribed during menopause. Post-menopausal 
women tend to suffer from depression and are prescribed antidepressants – in addition to 
hormone therapy. Estrogen replacement therapy is a topic that engenders debate since 
several studies contradict its efficacy as a palliative therapy for cognitive decline and 
neurodegenerative diseases. Signaling transduction pathways can alter brain cell activity, 
survival, and morphology by facilitating transcription factor DNA binding and protein 
production. The steroidal hormone estrogen and the anti-depressant drug lithium interact 
through these signaling transduction pathways facilitating transcription factor 
activation. The paucity of data on how combined hormones and antidepressants interact 
in regulating gene expression led me to hypothesize that in primary mixed brain cell 
cultures, combined 17β-estradiol (E2) and lithium chloride (LiCl) (E2/LiCl) will alter 
genetic expression of markers involved in synaptic plasticity and neuroprotection. Results 
from these studies indicated that a 48 h treatment of E2/LiCl reduced glutamate receptor 
subunit genetic expression, but increased neurotrophic factor and estrogen receptor 
 vi 
genetic expression. Combined treatment also failed to protect brain cell cultures from 
glutamate excitotoxicity.   
If lithium facilitates protein signaling pathways mediated by estrogen, can lithium 
alone serve as a palliative treatment for post-menopause? This question led me to 
hypothesize that in estrogen-deficient mice, lithium alone will increase episodic memory 
(tested via object recognition), and enhance expression in the brain of factors involved in 
anti-apoptosis, learning and memory. I used bilaterally ovariectomized (bOVX) 
C57BL/6J mice treated with LiCl for one month. Results indicated that LiCl-treated 
bOVX mice increased performance in object recognition compared with non-treated 
bOVX. Increased performance in LiCl-treated bOVX mice coincided with augmented 
genetic and protein expression in the brain. Understanding the molecular pathways of 
estrogen will assist in identifying a palliative therapy for menopause-related dementia, 
and lithium may serve this purpose by acting as a selective estrogen-mediated signaling 
modulator. 
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PREFACE 
 
Prior to my acceptance into the Biological Sciences graduate program at Florida 
International University I volunteered in the laboratory of my major advisor, Dr. Ophelia 
Inez Weeks.  I was immediately assigned to statistically analyze and interpret a 
behavioral study conducted by Dr. Claude-Henry Volmar, at the time a former Biology 
master’s graduate.  The behavioral study was to test the performance of lithium-treated 
C57BL/6J male mice on an object recognition task (ORT), a task that measures episodic 
memory.  An ORT involves mice recalling specific objects they were primed to 
remember and their ability in recognizing novel objects.  The hypothesis was that the 
lithium-treated group will spend a greater amount of time with the novel object compared 
with the control group.  Statistical analysis of these experiments supported the hypothesis 
that in these mice lithium increases episodic memory (e.g., novel object recognition).  
Shortly after, an undergraduate at the time, Pablo Penaloza, analyzed lithium content 
using blood samples from treated and control mice.  Lithium-treated mice showed a 
higher lithium-blood content than control.  Later, during my pre-doctoral studies, I 
showed the lithium dosage used in the ORT study increases inhibition of a multifaceted 
enzyme controlling transcription, cell death, mood-disorders, and neurodegenerative 
diseases (a topic discussed throughout this dissertation). 
 
Using the same blood samples from the ORT study, Pablo and I hypothesized that 
since lithium and estrogen affect similar molecular pathways in the brain, there will be an 
inverse correlation in estrogen versus lithium content in the blood – low estrogen content 
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with high lithium content or vice versa.  Results from this analysis rejected our 
hypothesis, since lithium raised estrogen levels in murine serum (unpublished data) – I 
was still interested in the molecular relation lithium and estrogen share, though.  These 
molecular relations led to the overarching goal of my dissertation, that is: 1) to provide a 
better understanding of how lithium and estrogen affect specific molecular markers in the 
brain related to cell growth and survival (e.g. neuroprotection), learning and memory; 
and, 2) if lithium alone can increase these molecular markers and increase episodic 
memory in an estrogen-deficient model.  I anticipate that a better understanding of such 
mechanisms will offer avenues for developing palliative therapies for postmenopausal-
related cognitive decline and neurodegeneration. 
 
To answer whether or not lithium influences estrogen-related pathways I used 
primary brain cell cultures of fetal C57BL/6J mice (the highlights from those experiments 
are noted in chapters one and two of my dissertation).  I initially intended to harvest and 
culture neurons for these experiments, unfortunately I cultured glia, the dominant brain 
cell type.  Glia not only provides support, nutrition, and maintenance of neurons but also 
facilitates neuronal communication and growth.  Notwithstanding, I continued to analyze 
these samples and something fascinating happened: I obtained viable and interesting 
results.  I used quantitative polymerase chain reaction (qPCR) and cell viability assays to 
generate and interpret data, revealing that lithium reduced estrogen-regulated gene 
expression of glutamate receptors involved in learning and memory.  Furthermore, 
lithium provided protection to glial cells against toxic levels of glutamate, and estrogen 
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reduced this protective quality.  A manuscript derived from these studies was submitted 
and accepted to the journal Brain Research.   
 
Using the genetic material from these same experiments I generated another 
manuscript (chapter two).  The second set of analyses addressed how combined treatment 
of estrogen and lithium affect gene expression of factors involved in learning, memory, 
and neuroprotection.  Using qPCR interpreted data showed that combined treatment of 
estrogen and lithium increases factors (i.e., transcription factors, proteins) involved in 
learning and memory, but not neuroprotection among glia-rich cultures.   
Chapter two is currently under review for publication in the journal Neuroscience Letters. 
 
To test whether lithium alone can enhance learning and memory (and molecular 
markers involved in these processes), I used estrogen-deficient mice (i.e. both ovaries 
were removed).  Estrogen-deficient mice were treated with lithium for one month.  This 
project utilized all the techniques I acquired up to this point to examine cognitive, 
neuroendocrine and biochemical parameters.  Results are specified in chapter three, and 
indicate that lithium-treated estrogen-deficient mice, compared with non-treated 
estrogen-deficient mice, show an increased performance in ORT (e.g. episodic memory).  
The observed increase in performance coincides with an increase in specific molecular 
makers in the brain involved in learning, memory and neuroprotection.  
 
The final chapter of my dissertation (chapter four) is a literature review aided by 
protein modeling techniques and in silico research.  Chapter four examines how lithium 
 4 
and estrogen affect similar proteins involved in neuroprotection, learning and memory.  
Extensive reports have examined neurological pathways associated with lithium and 
estrogen individually, and my review serves as a bridge between lithium and estrogen by 
recognizing possible links between them – in a molecular sense.  I chose this as my last 
chapter to encapsulate a theoretical mechanism of my dissertation and to provide a 
platform for future studies incorporating my experimental parameters. 
 
Ultimately, my dissertation investigates how estrogen and lithium affect 
molecular markers in the brain involved in learning, memory and neuroprotection.  Post-
menopausal women suffer from a lack of circulating estrogen and are often prescribed 
hormone replacement therapy; but some also suffer from depression and are often 
prescribed antidepressants.  Understanding the interactions of estrogen and lithium will 
provide a better treatment regime for post-menopausal women.  As I show in this 
dissertation, lithium alone increases episodic memory in estrogen-deficient mice.  This 
interpretation may market lithium as a palliative treatment for post-menopausal-related 
cognitive decline – although lithium is traditionally used for treating psychiatric 
disorders. 
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CHAPTER I 
Estradiol and Lithium Chloride Specifically Alter Glutamate Receptor Subunit Genetic 
Expression and Excitotoxicity in Primary Cultures 
 
Abstract 
Glutamate facilitates calcium influx via N-methyl-D-aspartate (NMDA) receptor, and 
excess calcium influx increases excitotoxicity – a pathological characteristic of 
neurological diseases.  Both 17β-estradiol (E2) and lithium influence NMDA receptor 
expression/signaling and excitotoxicity.  This led me to hypothesize that combined E2 
and lithium will alter NMDA receptor expression and excitotoxicity.  I tested this 
hypothesis using primary cell cultures from the cortex and hippocampus of C57BL/6J 
fetal mice pretreated with E2, lithium chloride (LiCl) and combined E2/LiCl for 12, 24 or 
48 h.  I examined cultures for brain cell type and changes in cell type caused by 
experimental procedures using glia and neuron gene specific primers.  These cultures 
expressed increased glial fibrillary acidic protein (GFAP) mRNA with low 
neurofilament-heavy chain (NF-H) mRNA expression.  Subsequent analysis of cortical 
cell cultures indicated that combined E2/LiCl decreased NR1 mRNA expression after a 
12 and 48 h treatment period.  Combined E2/LiCl also reduced NR1 mRNA expression 
in hippocampal cultures but only after a 48 h treatment period.  Hippocampal LiCl-
treated cultures also reduced NR1 mRNA expression after a 24 and 48 h treatment.  I 
next examined the response of 48 h pretreated cultures to a toxic level of glutamate.  
Excitotoxicity was measured using fluorescein diacetate/propidium iodide (FDA/PI) cell 
viability assay.  Results from FDA/PI assay revealed that LiCl pretreatment increased 
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viability for cortical cultures while E2 and combined E2/LiCl reduced viability.  All 
pretreatments for hippocampal cultures failed to increase viability.  My results showed 
combined E2/LiCl reduced NR1 mRNA and prevented protection against glutamate 
excitotoxicity in glial primary cultures.   
 
1.1 Introduction 
Estrogen-mediated neurobiological processes are involved in a myriad of signal 
transduction pathways.  These pathways result in enhancing synaptic plasticity [31], 
reducing apoptotic activity in cortical neurons [21], regulating neurotrophic factors [55], 
and facilitating transcription factor activation – e.g. cAMP response element binding 
protein (CREB) [36].  Estrogen is considered an activating agent in N-methyl-D-aspartate 
(NMDA) receptor signaling pathways [24], and NMDA receptor forms a heteromeric 
glutamate receptor composed of the subunits NR1, NR2A-D and NR3 [56].  Expression 
of NR1, NMDA receptor critical subunit, is increased in estrogen-induced primary 
hippocampal neuronal cell cultures [24].  Similar cultures show increased levels of 
intracellular calcium, mediated by the activation of L-type calcium channels, which in 
turn promote signaling pathways that activate/phosphorylate CREB.  This 
activation/phosphorylation promotes anti-apoptotic events [59].  Estrogen also facilitates 
a transient activation of glycogen synthase kinase-3beta (GSK-3β).  Estrogen receptor-
α (ER-α), when bound by its ligand estrogen, forms a complex with GSK-3β that 
facilitates regulation of beta-catenin transcriptional properties [7].  Response element 
binding of ER-α  relies on GSK-3β phosphorylation and this phosphorylation is inhibited 
in the presence of lithium [37].  Contrary to this synergistic relation of ER-α and GSK-
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3β, other studies show estrogen facilitating an inhibition of GSK-3β.  This inhibition is 
dependent on kinase phosphorylation mediated by estrogen receptor signaling [16].  
Interestingly, GSK-3β activity influences NMDA receptor signaling and NMDA receptor 
subunit expression.  Electrophysiological studies using mouse hippocampal slices report 
that GSK-3β activity is increased during long-term depression.  This increase reduces 
during NMDA receptor-mediated long-term potentiation [46].  Selective GSK-
3β inhibitors also reduce NMDA receptor synaptic currents and receptor internalization 
in cortical cell cultures.  Cultures expressing a knockdown of GSK-3β exhibit similar 
effects [8].   
 
Over a decade has passed since Klein and Melton (1996) demonstrated lithium 
specifically inhibiting GSK-3β [28].  This inhibition is associated with reducing apoptotic 
activity [22], increasing neurotrophic factors [2], and facilitating CREB DNA binding 
[17, 45].  Though the mechanism remains elusive, lithium indirectly inhibits GSK-3β by 
activating protein kinases that phosphorylate GSK-3β at serine 9 and/or by inactivating 
phosphatases that remove this phosphate group [26].  Direct inhibition involves lithium 
acting as a competitive inhibitor of magnesium; magnesium being a cofactor for ATP in 
GSK-3β activation [52].   Aside from lithium’s inhibitory action on GSK-3β, there is an 
indirect effect on NMDA receptor signaling pathway.  This involves reducing 
phosphorylation/activation of Src tyrosine kinases, potentially affecting any NMDA 
receptor-regulated excitotoxicity.  Phosphorylation of NR2 subunits of NMDA receptor 
by Src tyrosine kinases is essential for the receptor’s signal transduction activity [see 18].  
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Using lithium-treated rat cerebral cortex neurons, Hashimoto et al. (2003) demonstrated 
that phosphorylated levels of Src tyrosine kinase is decreased in a time-dependent 
fashion.  Lithium, however, does not seem to influence NMDA receptor subunit protein 
expression [44]. 
 
Expression of NR1 increases in estrogen-treated primary hippocampal neuronal 
cultures [24], and similar cultures also show increase intracellular calcium levels [59].  
But lithium reduces NMDA receptor-mediated glutamate excitotoxicity by reducing 
calcium influx [10].  While NMDA receptor is classically regarded as a neuronal 
receptor, these receptors are also found on cortical astrocytes [12].  Astrocytes process 
the neurotransmitter glutamate to reduce excitotoxic insults to neurons; however, 
astrocytes themselves are not as susceptible to excitotoxicity as are neurons [see 35].  In 
astrocyte cultures from the rat olfactory bulb, estrogen receptor agonists reduce secretion 
of specific markers responsible for inflammatory responses (e.g. interleukin-1, tumor 
necrosis factor-α, and matrix metallopeptidase 9) [32].  As well, astrocytes produce and 
secrete estrogen, influencing communication among neurons.  When cultures of rat 
cortical neurons are exposed to media from cultured astrocytes, neuronal synaptic 
formation and impulse transmission increase, due to the presence of estrogen in the 
astrocytic media [23].   
 
Glutamate excitotoxicity mediated by NMDA receptor is a pathological element 
in many neurodegenerative diseases and analysis of how combined estrogen and lithium 
influence NMDA receptor regulation and its mediated pathways are wanting.  Since 
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estrogen and lithium are involved in regulating NMDA receptor activation/function I 
hypothesized that combined estrogen (specifically 17β-estradiol; E2) and lithium chloride 
(LiCl) (E2/LiCl) will alter mRNA expression of NMDA receptor subunit NR1 in primary 
cultures harvested from mouse cortex and hippocampus.  The premise of this hypothesis 
is that estrogen receptor-α facilitates NMDA receptor subunit expression and studies 
have shown that estrogen receptor-α response element binding is attenuated in the 
presence of lithium [37].  My results indicate that combined E2/LiCl treatment reduce 
NR1 mRNA expression of primary cultures expressing high levels of glial-specific 
mRNA.  I chose this course of study since glia express NR1 [12], and NR1 is the critical 
subunit of a functional NMDA receptor.  These results led me to further hypothesize that 
amongst these primary glial cultures combined E2/LiCl will alter protective features (cell 
viability) against glutamate insult.  I tested this hypothesis using a cell viability assay 
with 48 h pre-treated primary cultures exposed to high levels of glutamate.  High 
glutamate concentration was necessary since glia are extremely tolerant to excitotoxicity 
[see 35].  My results indicated that while LiCl reduced NR1 mRNA in E2-treated 
cultures, E2 compromised cell viability in LiCl treated cultures.  In many instances post-
menopausal women undergoing hormone therapy are also prescribed lithium (for 
depression) and the interaction of these two agents are poorly understood.  This is the 
first study to note the influence of combined E2/LiCl on expression of receptors involved 
in learning, memory and mediating excitotoxic effects. 
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1.2 Experimental Procedures 
1.2.1 Primary Mixed Brain Cell Cultures 
I used C57BL/6J mice bred at Florida International University.  Animals 
were kept in an environment of 22°C temperature, 60% humidity, within 
polycarbonate transparent cages (26.7 cm x 20.6 cm x 14 cm) on a 12 h day-night 
cycle with free access to water and food.  All experiments were approved by the 
Institutional Animal Care and Use Committee (Approval Number: 08-017). 
Primary cultures were harvested from E18.5 C57BL/6J mice.  Pregnant mice (n = 
5) were euthanized by cervical dislocation, E18.5 fetal mice were then removed 
via caesarian section, decapitated, brains removed, and placed in ice-cold Earle’s 
balanced salt solution (EBSS; Hyclone, Utah).  The cortex and hippocampus from 
each hemisphere were isolated under a dissecting microscope and washed with 
fresh ice-cold EBSS.  Tissue was mechanically triturated, passed through a 70µm 
pore filter, and cells were counted using a hemocytometer.  Disassociated cells 
were randomly plated (6 x 106 for cortical cultures and 3 x 106 for hippocampal 
cultures) on poly-D-lysine (100µg/mL; Sigma-Aldrich, Missouri) coated 12-well 
plates containing B27/Neurobasal medium (Invitrogen, California) with 0.5mM 
L-glutamine and 4µg/mL gentamicin.  Additional 12-well plates, with poly-D-
lysine (100µg/mL) coated coverslips were set aside for viability assessment.  
Cells were maintained in a humidified, 5% CO2 atmosphere incubator with a set 
temperature of 37°C.  After 4 days in culture, the media was removed entirely and 
replaced with fresh media; half of the media was changed every 4 days, thereafter, 
until E2 and/or LiCl treatment. 
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1.2.2 Chemicals and Treatments  
After twelve days in culture, the media was removed entirely and replaced 
with media treated with 10mM LiCl (Sigma-Aldrich, Missouri), 0.04µM E2 
(Sigma-Aldrich, Missouri), or combined E2 and LiCl.  Duration of treatment for 
each group was 12, 24, and 48 h.  Additionally, cell viability was measured using 
48 h pretreated cells exposed to 100µM glutamatic acid (Sigma-Aldrich, 
Missouri) for 1 h at 37°C.  
 
1.3 Experimental Techniques  
1.3.1 Total RNA Isolation and cDNA Synthesis 
Total RNA was extracted from cultured cells after treatment with TRIzol reagent 
(GIBCO, California), according to manufacturer’s protocol.  Briefly, cultures were rinsed 
with ice-cold DPBS, TRIzol Reagent (600µL-1mL) was added directly into each well, 
and cultures were homogenized.  Homogenized cells were then transferred to a fresh 
tube, and incubated at room temperature.  Chloroform was added and centrifuged at       
10, 000 rpm at 4°C.  Total RNA (aqueous phase) was transferred to a sterile tube and 
allowed to precipitate with isopropanol and glycogen overnight at -20°C.  The RNA was 
pelleted via centrifugation at 10, 000 rpm at 4°C, supernatant was decanted and RNA 
pellet was washed twice with 75 % ethanol.  Pellets were then air dried and resuspended 
with DEPC-treated water.  Contaminants of DNA were removed with the RQ1 DNase kit 
(Promega, Wisconsin).  Samples were stored at -80°C until they were further processed. 
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Reverse transcription (RT) was performed using SUPERSCRIPTTM II RNase H-
free reverse transcriptase (Invitrogen, California), according to the manufacturer's 
protocol.  Briefly, 500ng of total RNA was reverse transcribed with 0.05µg/µl of Oligo 
(dT)12-18 at 65°C for 5 minutes.  First strand cDNA was synthesized with 5mM MgCl2, 
10mM DTT, and 1.5 units Superscript II and incubated at 42°C for 50 minutes; reaction 
was terminated at 70°C for 15 minutes.  The RNase H (Invitrogen, California) was 
incubated at 37°C for 20 minutes once the first strand was synthesized to remove any 
remaining RNA. 
 
1.3.2 Cell-Typing Cultures using RT-PCR and Gel Electrophoresis   
First strand cDNA was amplified via real time polymerase chain reaction (PCR) 
using NF-H (forward primer 5'-AGCCCAAGGACTCTACAGCA-3'; reverse primer, 5'-
CTTTGGCTTTTCCGTCTCTG-3') and GFAP (forward primer 5'-
AGAAAACCGCATCACCATTC-3'; reverse primer, 5'-TCACATCACCACGTCCTTGT 
-3') and GoTaq® (Promega, Wisconsin).  Cycling parameters for an Eppendorf 
Mastercycler Gradient were set for: denaturing at 95°C for 30 seconds, annealing 
temperature of 57°C or 64°C for 30 seconds, and extension at 72°C for 30 seconds, for a 
total of 30 cycles, followed by a final extension at 72°C for 10 minutes.  After 
amplification, samples were subjected to gel electrophoresis using a 1.5% agarose gel 
stained with ethidium bromide and photographed using Digital Imaging Filter/Ethidium 
Bromide (Fotodyne, Wisconsin) under UV light.  Resulting band intensities were based 
on two replicates and analyzed using ImageJ software band analyzer [49].  Measurements 
are represented in arbitrary units and obtained by dividing the pixel integrated density 
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(integrated density = area x mean pixel value) from each band of NF-H or GFAP by the 
absolute intensity of the standard – HPRT.   
 
1.3.3 Quantitative Real Time RT-PCR  
First strand cDNA was amplified via real time PCR using SYBR Green PCR 
master mix (ABgene, New York), 200-300nM of forward and reverse primers using 
iCycler (BioRad, California) with IQ iCycler software (version 3.1).  Cycling parameters 
were set at: 95°C 15s, 57°C 30s, and extension at 72°C for 30s, for a total of 40 cycles, 
followed by a final extension at 72°C for 10 minutes.  The specific primer pairs were: 
NMDA receptor subunit NR1: forward primer, 5'-ACTCCCAACGACCACTTCAC-3; 
reverse primer, 5'-GTAGACGCGCATCATCTCAA-3'; HPRT: forward primer, 5'-
GGAGCGGTAGCACCTCCT-3'; reverse primer, 5'-AATCCAGCAGGTCAGCAAAG-
3'.  All samples were compared with a standard curve comprised of pDNA of HPRT and 
NR1 with pDNA generated using TOPO TA Cloning® Kit (Invitrogen, California).  
Readings were normalized by dividing mRNA starting quantity (SQ) of NR1 by the 
house-keeping gene HPRT mRNA SQ; output is in femtograms (fg) of mRNA.   
 
1.3.4 Cell Viability – Fluorescein Diacetate/Propidium Iodide Assay  
Cortical and hippocampal cells were cultured on 18mm coverslips cultures and 
pretreated for 48 h with E2, LiCl, and combined E2 and LiCl (as described previously).  
Excitotoxicity was induced for 1 h with 100µM glutamate.  Cell viability of cultures was 
determined after glutamate excitotoxicity through the use of a fluorescein diacetate-
propidium iodide labeling technique [25].  Briefly, cells were quickly rinsed with ice-cold 
 14 
Dulbecco’s Phosphate Buffer Saline (DPBS).  Approximately 150µL cocktail of 2µg/mL 
of fluorescein diacetate and 0.6µg/mL propidium iodide was added directly to the 
coverslip with adhered cells and incubated at room temperature.  Each 18mm coverslip 
was placed against a grid and images were captured from five subdivisions on the grid 
(upper right, upper left, lower right, lower left, and center).  Images were captured from 3 
replicates per subdivision – a total of 15 images per coverslip – with a Leica inverted 
epifluorescent microscope with a QImaging Micropublisher 3.3 cooled RTV camera and 
processed using ImageJ Cell Counter.  For a comparison prior to any experimental 
procedure I assayed a separate culture designated as Initial Viability.   
 
1.3.5 Statistical Analysis 
Data are presented as the mean ± S.E.M and statistical significance was 
determined by analysis of variance (ANOVA) followed by Fisher’s least significant 
difference (LSD) post-hoc testing.  Significant differences have a p-value < .05.  All 
results were obtained from two separate experimental procedures – except for glutamate 
excitotoxicity which was based on triplicates from one experiment (see section 4.3.4 in 
Experimental Procedures).  Each level for all factors was randomly determined. 
 
1.4 Results  
1.4.1 Brain cell typing of primary cultures indicated predominance for glia  
Figures 1A-D depicts densitometric data (gene/HPRT) obtained after RT-PCR 
and gel electrophoresis (gels represented above the graph).  I chose to analyze brain cell 
type using gene specific primers for neurons and glia.  The use of specific primers 
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allowed me to monitor brain cell type and to monitor how my experimental parameters 
affected neuronal and glial gene expression.  I used gene specific primers for glial 
fibrillary acidic protein (GFAP) and neurofilament heavy chain (NF-H), markers readily 
used for identifying glial and neuronal populations, respectively.  Using ANOVA, 
densitometric data indicated a significant difference in gene expression (p < .001).  These 
primary cell cultures expressed high levels of GFAP mRNA (figures 1A & C) but with 
consistently low levels of NF-H mRNA (figures 1B & D).  
 
My experimental parameters altered genes expression for cortical but not 
hippocampal cultures.  Expression of GFAP mRNA gradually increased for cortical 
cultures during the 12, 24, and 48 h period (figure 1A), while hippocampal cultures 
maintained consistency in GFAP expression (figure 1B).  Expression of NF-H, however, 
was more abundant in hippocampal cultures (figure 1D) compared with cortical cultures 
(figure 1B) and this was consistent throughout treatment periods.  Treatment did not 
affect GFAP or NF-H mRNA expression within each respective culture type (cortical or 
hippocampal). Overall, densitometric data demonstrated that both culture types expressed 
high levels of GFAP mRNA compared with NF-H indicating these cultures were 
predominantly glial.   
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Figures 1A-D: ImageJ densitometric data obtained from RT-PCR and electrophoresis. 
Analysis was performed via electrophoresis of RT-PCR samples using a 1.5% agarose 
gel, gel images captured, and analyzed using ImageJ.  Low visibilities of bands are due to 
low mRNA expression.  Total RNA from and reverse transcribed E18.5 cortical (A & B) 
and hippocampal (C & D) primary cell cultures were isolated from Control (no 
treatment), 0.04µM E2, 10mM LiCl, and combined E2/LiCl treated for 12, 24, and 48 h.  
cDNA was then amplified via PCR using gene specific primers for GFAP (A & C) or 
NF-H (B & D).  Measurements were based on relative pixel intensity (integrated intensity 
of GFAP/HPRT or NF-H/HPRT) and expressed in arbitrary units. Gels are represented 
for each gene and treatment period (represented above the graph).  
  
 
1.4.2 Combined E2/LiCl treatment reduced NR1 mRNA expression 
Next, I examined the effect of my experimental design on NR1 mRNA 
expression.  The critical subunit of the NMDA receptor is NR1 and no studies have 
investigated how combined E2/LiCl affects NR1 expression in glial cultures.  
Additionally, in analyzing NR1 gene expression I can postulate transcriptional activity 
caused by my treatment parameters.  Interpretation of ANOVA on real time RT-PCR data 
showed significant differences (p < .001) in NR1 mRNA expression related to treatment.  
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Both treated culture types (cortical and hippocampal) slightly differed in overall NR1 
mRNA expression (figures 2A & B), but this difference was not significant (p > .057).  
No significant changes were noted across treatment periods (p > .2) – e.g., in a time-
dependent fashion; although, NR1 expression significantly changed among treated 
culture types at specific time periods (p < .001). 
2A. 
 
 
 
 
 
 
 
 
 
 
2B. 
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Figures 2A-B: Quantitative RT-PCR of NR1 mRNA expression. E18.5 cortical (A) and 
hippocampal (B) primary cell cultures treated for 12, 24, and 48 h with 0.04µM E2, 
10mM LiCl, combined E2/LiCl, or Control (no treatment).  After temporal treatment total 
RNA was isolated and reverse transcribed.  The figure denotes NR1 mRNA expression in 
femtograms (y-axis) and treatment duration (x-axis).  *, p-value < .05 compared with 
control; #, p-value < .05 compared with E2; †, p-value < .001 compared with 12 h 
treatment. 
 
 
No significant effects were detected for Control or E2 treatment on NR1 mRNA 
expression across treatment periods and culture type (figure 2A & B).  Expression of 
NR1 was influenced by LiCl, but this alteration was dependent on culture type.  In 
cortical cultures (figure 2A), LiCl seemed to reduce NR1 gradually and specifically after 
a 48 h treatment period, but according to Fisher’s LSD this decrease proved to be non-
significant (p > .1).  For hippocampal cultures, Fisher’s LSD indicated that LiCl 
significantly decreased (p < 0.05) NR1 mRNA expression after a 24 and 48 h treatment 
period when compared with the 12 h treatment period (figure 2B).  Also, LiCl 
significantly reduced (p < 0.05) NR1 expression in hippocampal cultures after a 48 h 
treatment period when compared with Control and E2 treatments (figure 2B).  Although 
all treatments appeared to reduce hippocampal culture NR1 gene expression after 12 h 
when compared with Control (figure 2B), Fisher’s LSD indicated this change was non-
significant (p > .05).   
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Combined E2/LiCl treatment significantly decreased (p < .05) NR1 mRNA 
expression in both cortical and hippocampal cultures (figure 2A & B).  Fisher’s LSD 
showed that combined E2/LiCl treatment significantly reduced cortical NR1 mRNA 
expression after 12 h when compared with E2 treated cultures (figure 2A).  This 
significant decrease reoccurred after cortical cultures were treated with combined 
E2/LiCl for 48 h.  The 48 h decrease was noted when combined E2/LiCl was compared 
with E2 and Control (figure 2A).  Cortical cultures treated after 24 h did not alter NR1 
mRNA expression.  In hippocampal cultures, combined E2/LiCl treatment significantly 
reduced NR1 expression.  Combined E2/LiCl treatment when compared with Control and 
E2 significantly reduced (p < 0.05) NR1 expression after a 48 h treatment period (figure 
2B).  No significant differences were noted for combined E2/LiCl treated hippocampal 
cultures after a 12 and 24 h treatment, though.   
 
These results demonstrated that combined E2/LiCl treatment decreased NR1 gene 
expression for both culture types, specifically after a 48 h treatment period.  Cortical 
cultures showed significantly decreased NR1 gene expression after 12 and 48 h treatment 
periods and hippocampal cultures showed significantly decreased expression only after a 
48 h treatment period.  Additionally, NR1 gene expression in LiCl-treated hippocampal 
cultures decreased after a 24 and 48 h when compared with 12 h treatment period.  
Cultures treated with E2 did not affect NR1 mRNA expression across all experimental 
parameters. 
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1.4.3 Combined E2/LiCl and E2 failed to reduce excitotoxicity  
Glia are extremely tolerant to excitotoxicity [see 35] and since my primary 
cultures express high glial mRNA (see figures 1A-D) a high dosage of glutamate 
(100µM) was necessary.  In my experiment, primary cell cultures were pretreated for 48 
h, subjected to excitotoxicity with glutamate, and assessed for cell viability using 
fluorescein diacetate/propidium iodide assay (FDA/PI).  Figure 3A displays captured 
images of primary cultures after experimental procedures.  Live cells were labeled green 
(FDA) and dead cells were labeled red (PI).  These primary cultures maintained a 
tolerance for glutamate toxicity without treatment (Control) when compared with Initial 
Viability (i.e., assayed prior to any experimental procedure).  Additionally, Control 
cortical cultures compared with Initial Viability showed an increase in FDA labeling 
(figure 3A).  Increased Control FDA labeling did not occur for hippocampal cultures, 
though (figure 3A).  Pretreatment with E2 and combined E2/LiCl decreased viability for 
both cortical or hippocampal cultures, as indicated by the intense PI labeling; however, 
LiCl-treated cortical cultures showed increased cell viability which did not occur for 
hippocampal (figure 3A).  These images were then processed using ImageJ cell counter 
[49] and data generated were statistically analyzed using ANOVA. 
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Figure 3A-3B: Mean viability for glutamate excitotoxicity from 48 h treated cortical 
(grey bars) and hippocampal (black bars) primary cell cultures. A pre-treatment 
measurement (Initial viability) was assayed to note any changes caused by the treatment 
and glutamate excitotoxicity.  Images were captured (green labeling, fluorescein diacetate 
(FDA; live cells) and red labeling, propidium iodide (PI; dead cells)) and viability 
(FDA/(FDA+PI)) was assessed using ImageJ Cell Counter for both cortical and 
hippocampal primary cultures. *, significantly reduced cell viability compared with 
Initial Viability and Control (p-value < .05); #, significantly increased cell viability when 
compared with Initial Viability (p-value < .05); †, significantly increased cell viability 
when compared with other treatments (p-value < .05).  
 
 
Viability was not reduced for Control cortical and hippocampal cultures when 
compared with Initial Viability after glutamate excitotoxicity (figure 3B); specifically in 
Control cortical cultures where viability significantly increased (p < .05) (figure 3B).  
Figure 3B indicated cortical cultures pretreated with E2 and combined E2/LiCl 
significantly failed to rescue cells from glutamate excitotoxicity when compared with 
Control and Initial Viability.  Cortical cultures treated with LiCl, however, exhibited 
increased cell viability when compared with other treatment types and Initial Viability 
(figure 3B).  Figure 3B also depicts that all pretreated hippocampal cultures failed to 
rescue cells from glutamate excitotoxicity when compared with Control and Initial 
Viability.  Hippocampal cultures also did not display increased cell viability because of 
glutamate (e.g. Control) as did cortical cultures. 
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1.5 Discussion  
Several cell signaling transduction pathways are affected by E2 and LiCl, but few 
studies concentrate on any neurobiological effects the two combined may present.  
Additionally, investigations are wanting on how combined E2 and LiCl affect glia.  In the 
mammalian brain glia are ten times more numerous than neurons and such would be 
expected to play a role in the progression of neurodegenerative diseases [see 57].  In this 
study, densitometric results showed high levels of GFAP mRNA expression among 
cortical and hippocampal cultures (see figures 1A & C) compared with NF-H (see figures 
1B & D), suggesting a predominance of glia.  I chose to use GFAP and NF-H since these 
are standard markers in identifying brain cell type (glia or neuron, respectively).  Cultures 
used in this study were harvested at a late embryonic age (E18.5) when most neurons 
have differentiated.  As expected, neurons harvested at E18.5 would have a greater 
propensity for cell death during mechanical trituration, hence the low NF-H expression 
(see figures 1B & D).  Primarily, B27/Neurobasal medium is used for culturing cortical 
and hippocampal neurons and this medium generates a 90% neuronal population 
compared with a 10% glial population as described by immunocytochemistry [3].  Glia 
population percentage coincides with my FDA/PI assay of Initial Viability (e.g. viability 
assayed prior to any experimental procedures; see figures 3B) for both cortical and 
hippocampal cultures since B27/Neurobasal media maintained a neuronal population 
while suppressing glia proliferation.  This allowed me to maintain cultures that sustained 
neurons (see figures 1B & D), suppressed glia proliferation, but still with a predominance 
of glial cells (see figures 1A & C).  Densitometric data (figures 1A-D) indicated that 
cortical cultures increased and were higher in GFAP mRNA expression across treatment 
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periods (see figure 1A) compared with hippocampal cultures (see figure 1C).  Glia are 
constantly proliferating and this gradual increase and higher GFAP expression in cortical 
cultures could be explained since cortical cultures were plated at a higher density than 
hippocampal cultures (see Experimental Procedures).  Hippocampal cultures expressed 
higher levels of NF-H mRNA (see figure 1D) compared with cortical cultures (see figure 
1B), but still, with higher GFAP levels than NF-H (see figure 1C & D).  Rocha et al. 
(1994) indicated that GFAP protein expression increased in the caudate nucleus and 
hippocampus of 4 week lithium-treated rats [50] and though I noted GFAP mRNA 
increased in cortical cultures (specifically at 24 and 48 h; see figure 1A) this was not 
apparent in hippocampal cultures.  This may be a result of my treatment being an acute 
(up to 48 h) rather than a chronic one (4 weeks).   
 
Glia, like neurons, are also known to express functional NMDA receptor and non-
NMDA receptor [12, 30].  Glia NMDA receptor expression increases susceptibility to 
excitotoxicity and facilitates glutamate transport [see 35].  Glial susceptibility to 
excitotoxicity, however, is less severe than neuronal.  This is of specific interest since 
NMDA receptor subunit expression and excitotoxicity of glia are rarely studied.  The 
critical subunit of NMDA receptor is NR1 and without it there is no functional receptor.  
In studying glial NR1 gene expression within my experimental parameters I can postulate 
transcriptional activities affected (e.g., estrogen receptor-α/GSK-3β-mediated pathways 
or CREB).  Among both culture types, hippocampal cultures expressed higher levels of 
NR1 mRNA (see figure 2B) compared with cortical cultures; this difference is worth 
discussing even with p-value = .058 (see figure 2A).  Both cultures expressed high levels 
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of GFAP but hippocampal cultures also expressed higher levels of NF-H (see figure 1D) 
compared with cortical cultures (see figure 1B).  The higher levels of NR1 mRNA 
expression in hippocampal cultures is that glia express functional NMDA receptor at a 
lower level than neurons [see 11].  Additionally, autoradiography using NMDA receptor-
specific ligands depict higher density of NMDA receptor in hippocampal regions than 
cortical [41].  My study showed no effect of E2 treatment on NR1 mRNA expression for 
both culture types (see figures 2A & B).  My E2 results on NR1 mRNA contradicts Jelks 
et al. (2007) findings where E2 treatment increased NR1 in neuronal cultures [24], but 
my cultures did express higher levels of GFAP mRNA (see figures 1A & C).  Few 
studies investigate how E2 (or lithium) influence glia but I suggest my glia cultures 
reached a saturation point since glia also produce estrogen – as noted in astrocytic culture 
media [23].  The E2-estrogen receptor complex have a Kd of 150pM [53], therefore, 
doses of .04µM E2 may have been negligible in altering NR1 mRNA expression.  
Expression of NR1 mRNA did not change in LiCl-treated cortical cultures (see figures 
2A) across treatment periods which coincides with Hashimoto et al. (2002) who showed 
that lithium does not influence NR1 protein expression in neuronal cultures [19].  
Treatment of LiCl, however, did reduce NR1 mRNA expression in hippocampal cultures 
after a 24 and 48 h treatment period compared with 12 h LiCl-treatment (see figures 2B).  
Lithium diffuses into a cell via sodium channel but also through glutamate receptors [27].  
I clearly show that hippocampal cultures express higher levels of NR1 mRNA (see figure 
2B) than cortical cultures (see figure 2A) and this may be indicative of functionally 
expressed NMDA receptor.  Hippocampal NR1 mRNA down-regulation by LiCl may be 
caused by the influx rate of LiCl.  This rate will change NR1 expression since estrogen 
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receptor-α is involved in facilitating NMDA receptor subunit expression [see 58] that is 
mediated by GSK-3β [see 37]; and lithium is known as a selective inhibitor of GSK-3β 
[26]. 
 
The purpose of this study was to note the combined affect of E2 and LiCl on NR1 
mRNA expression and excitotoxicity.  After a 12 h treatment, NR1 expression for 
cortical cultures was not altered with individual treatment of E2 or LiCl; however, when 
LiCl was combined with E2, NR1 expression decreased after 12 h (see figure 2A).  
Hippocampal cultures did not display this reduction at 12 h, though (see figure 2B).  
Studies show that in rat cerebral cortex hormone and dopamine-stimulated adenyl cyclase 
activity is hindered by lithium [43].  Adenyl cyclase produces cAMP, a main constituent 
in CREB signaling pathway.  Activated CREB is highly involved in facilitating NMDA 
receptor subunit expression [48] and reduced NR1 at 12 h may be caused by LiCl 
inhibiting cortical adenyl cyclase activity triggered by E2.  Combined E2/LiCl did not 
alter NR1 expression in cortical and hippocampal cultures after 24 h treatment (see figure 
2A & B).  Therefore, the 12 h decrease in cortical NR1 mRNA may be caused by the fast 
action of extracellular LiCl concentration inhibiting adenyl cyclase activity [6] as 
opposed to intracellular concentration since reduced cortical NR1 mRNA reoccurred at 
48 h treatment period for both culture types.  The decrease in NR1 after 48 h was 
significant compared with Control and E2 treated cortical and hippocampal cultures (see 
figures 2A & B).  Reduced NR1 at 48 h with combined E2/LiCl occurred for both 
cultures indicating a similar pathway involved, possibly through the intracellular estrogen 
receptor-α/GSK-3β-mediated pathway [37].  Down-regulation of NR1 mRNA could be 
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explained since estrogen receptor-α, when bound by its ligand E2, facilitates NMDA 
receptor subunit gene expression by recognizing palindromic DNA sequences [58]; thus, 
E2 has a direct genomic role in NMDA receptor subunit expression.  Additionally, 
response element binding of estrogen receptor-α relies on GSK-3β phosphorylation and 
this phosphorylation is inhibited by lithium [37] since lithium is a selective inhibitor of 
GSK-3β [26].  I chose such high concentrations for E2 and LiCl based on the literature, 
since 10mM LiCl inhibits ~70% GSK-3β protein activity [52], and a 0.04µM 
concentration of E2 significantly increases bcl-2 expression – an anti-apoptotic protein – 
via calcium influx in cell cultures [59].  Medunjanin et al. [37] used MELN cells treated 
for 48 h with 30mM LiCl which decreased estrogen receptor-α response element binding 
and this decrease was the result of GSK-3β inhibition.  The aforementioned references 
provide insight into my results since LiCl significantly decreased NR1 mRNA expression 
in E2-treated cortical (see figure 2A) and hippocampal cultures (see figure 2B) after 48 h 
treatment period.  Since NR1 mRNA in E2-treated cells did not change, I deduce this 
reduction is the result of LiCl (potentially via inhibition of GSK-3β activity).  Whether or 
not LiCl influences estrogen receptor-α/GSK-3β-mediated pathway within my 
experimental parameters still remains to be elucidated.  I am currently working on 
experiments to test these effects.  Studies on NR1 protein level should be conducted 
under my experimental and treatment conditions.  Present results are represented in 
mRNA expression and post-transcription and/or post-translational influences may render 
differences at the protein level when compared.  Both estrogen and lithium alter the 
phosphorylation state of NMDA receptor subunits reducing NMDA receptor-mediated 
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excitotoxicity [13, 19, 34].  It will be interesting to note the phosphorylated state of 
NMDARs within my experimental parameters; however, within the scope of this project, 
I provide substantial evidence on that combined E2/LiCl alter excitotoxicity and NR1 
mRNA expression. 
 
Excitotoxicity mediated by NMDA receptor characterizes many neurological 
diseases [see 33].  The E2 concentration I chose for my experimental procedures 
(0.04µM) also provides neuroprotection for hippocampal cultures [9], and as mentioned, 
increases bcl-2 expression [59].  A concentration of 0.04µM E2 should provide 
neuroprotection against excitotoxicity, however, glia may respond differently to this 
treatment.  After pre-treating primary cultures for 48 h with E2 and/or LiCl I exposed 
these glial cultures to a toxic level of glutamate for 1 h.  Cortical cultures displayed 
higher viability with LiCl treatment compared with hippocampal cultures (see figures 3B 
& C).  NR1 (see figure 2B) and NF-H mRNA expression (see figure 1D) were higher in 
hippocampal cultures than cortical cultures (see figure 1B & 2A).  These observations 
could explain the extremely low viability in treated hippocampal cultures (see figure 3B) 
since excitotoxicity is mediated via NMDA receptor signaling.  The literature indicates 
that E2 and lithium affect NMDA receptor, but with opposing actions.  On the one hand, 
estrogen facilitates NMDA receptor-regulated calcium influx [59], but studies show 
estrogen’s neuroprotective qualities against glutamate insult are through calcium-
independent pathways [47].  On the other hand, lithium reduces calcium influx and 
NMDA receptor-mediated glutamate excitotoxicity [10, 18].  Normally, inducing 
excitotoxicity reduces viability among neuronal cultures, but glia are more tolerant to this 
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insult [see 35].  My cortical cultures exhibited high glia-associated GFAP mRNA 
expression (figures 1A).  Although hippocampal cultures showed this as well (see figures 
1C), hippocampal cultures also expressed higher levels of neuron-associated NF-H 
mRNA expression compared with cortical cultures (see figures 1B & D).  Results from 
FDA/PI assay (figures 3A-C) strengthen densitometric data since cortical and 
hippocampal cultures tolerated excitotoxicity as observed with Control, which was not 
significantly affected by such a high dosage of glutamate (see figures 3A-C).  Cortical 
cultures expressing higher levels GFAP mRNA (see figure 1A) also explain increased 
cell viability in Control and LiCl-treated cortical cultures (see figure 3B).  Treated 
hippocampal cultures (figure 3B) did not display this protective quality since 
hippocampal cultures also expressed higher levels of NF-H mRNA (see figure 1D). 
 
Previous literature specifies that both estrogen and lithium act as neuroprotective 
agents and may be used as a palliative treatment for neurodegeneration [10, 15, 51].  My 
study is the first to show that combined E2 and LiCl affect NR1 mRNA expression and 
excitotoxicity in cortical and hippocampal primary mixed brain cell cultures.  Studies of 
this caliber are wanting since little is known about how E2 and LiCl influence molecular 
processes of the brain.  Analysis of NMDA receptor subunit mRNA and protein 
expression using post-mortem Alzheimer’s disease (AD) brains show a decrease in NR1 
and NR2B in the hippocampal formation with advancement of the disease [38].  In a 
study using ovariectomized rats, estrogen-replacement did not affect NMDA receptor 
subunit mRNA expression; although, duration of ovariectomy did affect this expression 
[1].  In recent years, post-menopausal women are diagnosed with AD more often than 
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men and this statistic is related to estrogen deficiency [14].  Estrogen replacement therapy 
(ERT) proves to be beneficial to post-menopausal women in reducing the risk of 
developing AD [see 14].  Studies demonstrate that the dominant form of estrogen, 
estradiol, plays an important role in neuroprotection and enhancement of learning and 
memory [20].  The use of ERT is a subject of debate due to the risk of developing breast 
cancer.  This is marked by an increased incidence of lobular carcinoma in post-
menopausal women under ERT [42] and women suffering from depression during peri- 
and post-menopause are often prescribed lithium [4, 29].  Estrogen and lithium also 
affects the dopamine pathway, a pathway implicated in many clinical disorders and 
neurodegenerative diseases [40, 54].  An increase in dopaminergic pathways is a 
characteristic of bipolar disorder (manic-depression) and lithium is readily prescribed as a 
prophylactic for this disorder [54].  Studies show that combined E2/LiCl alter serotonin 
and dopamine metabolites. Ovariectomized rats treated with E2 show no change in 
frontal cortices levels of serotonin, dopamine or dopamine metabolites.  When E2 is 
combined with LiCl, though, dopamine is greatly decreased but show higher levels of 
serotonin and dopamine metabolites [39].  Additionally, NMDA agonist increase 
dopamine release modulated by hormones [5].  It will be worth studying the involvement 
of combined E2 and LiCl in the dopamine pathway and how these two agents affect 
NMDA receptor expression and function.  An understanding of underlying molecular 
mechanism in regards to how E2 and LiCl interact is lacking.  The present study 
introduces and advances perspectives for additional studies directed towards developing 
palliative therapies for neurodegeneration and postmenopausal-related cognitive decline.  
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CHAPTER II 
Combined Estradiol and Lithium Chloride Specifically Alter Factors Involved in 
Learning, Memory, but not Neuroprotection in Primary Cultures 
 
Abstract  
Estrogen replacement therapy (ERT) is commonly prescribed during menopause.  Post-
menopausal women also tend to suffer from depression and as a result are prescribed 
antidepressants – in addition to ERT.  Glia are the dominant brain cell type but little is 
known about how the combination of hormones and antidepressants affect glia.  
Investigations show that both hormones and antidepressants facilitate gene expression.  
The paucity of data on how combined hormones and antidepressants interact in regulating 
gene expression led me to hypothesize that in primary cultures of mixed brain cells 
predominated by glia, combined 17β-estradiol (E2) and lithium chloride (LiCl) (E2/LiCl) 
will alter mRNA expression of markers involved in synaptic plasticity and 
neuroprotection.  I recently published that 48 h treatment of E2/LiCl reduces glutamate 
receptor subunit mRNA expression and increases excitotoxicity in primary cultures of 
mixed hippocampal and cortical cells predominated by glia.  In the present study, I 
quantified mRNA expression of BDNF, Bcl-2 and ER-α using the cDNA of treated 
primary cultures of mixed brain cells from the previous chapter.  Results indicate that a 
48 h treatment period with combined E2/LiCl significantly increases BDNF and ER-α 
mRNA expression compared with Control and E2 treatment alone.  Increased ER-α 
mRNA expression, however, was culture specific – e.g. an increase in hippocampal but 
not cortical cultures.  No significant differences were noted for Bcl-2 mRNA expression, 
 40 
though.  These results add to the literature that combined hormones (E2) and 
antidepressants (LiCl) alter gene transcription of factors involved in learning and 
memory.  
 
2.1 Introduction 
 Estrogen replacement therapy (ERT) is a common prescription for menopause, 
specifically during post-menopausal stages.  Depression is common during menopause 
and as a result, women are prescribed antidepressants in combination with ERT [5, 27].  
It is unfortunate that few studies focus on the interacting properties of hormones and 
antidepressants since both influence a myriad of cell signaling pathways [23, 31].  
Estrogen is the main constituent diminished during menopause [2] and this depletion not 
only affects women physiologically but also has neurological implications [12].  Studies 
show that estrogen depletion influences astrocytosis, cell proliferation and differentiation 
of neurons [41].  A plethora of protein signaling cascades are facilitated by estrogen and 
these interactions result in gene expression of markers involved in cell survival, learning 
and memory among glia and neurons [31].  The two receptors for estrogen are estrogen 
receptor α and β (ER-α and ER-β) and these receptors play a role in facilitating estrogen-
mediated glial [9] and neuronal [31] protein signaling cascades.  Studies also show the 
co-expression of brain derived neurotrophic factor (BDNF) and ER-α among pyramidal 
cells of rat hippocampus [45], but BDNF drastically decreases in people suffering from 
neurodegenerative disorders [44].  Although BDNF expression is noted primarily among 
neurons [19], BDNF is also shown to be co-expressed among glia in rat cortical and 
hippocampal areas [39] and in mouse primary glia cultures [21].  Estrogen, via ER-α, 
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increases BDNF expression and facilitates BDNF-tyrosine kinase receptor signaling in 
both glia and neurons [44].  Anti-apoptotic factors are also affected by ER-α.  Astrocytic 
co-expression of B-cell lymphoma/leukemia-2 (Bcl-2) and ER-α in the hippocampus of 
post-mortem brains of Alzheimer’s disease (AD) patients indicates a potential mechanism 
for ER-α neuroprotection [9, 29].  Additionally, ER-α expression increases in AD 
patients compared with controls [29].   
 
 Lithium is commonly used to treat bipolar disorder, and it is now over a decade 
since lithium was identified as a specific inhibitor of glycogen synthase kinase-3beta 
(GSK-3β) [25], and molecular implications for lithium continue to be explored.  Similar 
to estrogen, lithium facilitates gene expression responsible for anti-apoptosis, learning 
and memory [30].  Lithium indirectly facilitates gene expression by interacting with 
GSK-3β, an enzyme highly involved in development, gene expression, and cell signaling 
regulation as reviewed by Grimes and Jope [15].  Among neurons, lithium-GSK-
3β inhibition is associated with reducing apoptosis [20], increasing neurotrophic factors 
[1], and facilitating DNA binding of transcription factors [14, 37].  Lithium also affects 
astrocytic pH levels that stimulate myo-inositol transport systems, ultimately affecting 
protein signaling pathways in astrocytes [46].  Inositol signaling is known to be regulated 
by proline-, glutamic acid-, and leucine-rich protein-1 (PELP1), a co-regulator of ER-α 
signaling [35]. 
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There is a paucity of studies on how various treatments interact with one another 
(through physiological and/or molecular processes).  I recently published a study 
focusing on combined effects of estradiol (17β-estradiol; E2) and lithium chloride (LiCl) 
(E2/LiCl) on glial NMDAR subunit NR1 gene expression and glutamate excitotoxicity.  I 
showed that a 48 h E2/LiCl treatment reduced NR1 gene expression and increased 
glutamate excitotoxicity in mouse hippocampal and cortical primary cultures of mixed 
brain cells predominated by glia [48].  In the present study, I use the same cDNA from 
treated primary cultures of mixed brain cells from previous chapter to further investigate 
how combined E2/LiCl influence gene expression.  Both estrogen and lithium directly 
and/or indirectly influence gene expression of factors involved in learning, memory and 
neuroprotection [23, 31], which led me to hypothesize that combined E2/LiCl will alter 
BDNF, Bcl-2, and ER-α mRNA expression in these cultures.  My results indicate that a 
48 h E2/LiCl treatment increases BDNF, ER-α mRNA, but not Bcl-2 mRNA expression 
in mouse primary mixed cultures.  I also note that these results differed according to 
culture type (hippocampal versus cortical cultures).  My data does present developmental 
differences since results are generated from embryonic brain cell cultures. Still, I believe 
my results will help elucidate interactions of hormones and antidepressants and how they 
affect gene expression of proteins involved in learning, memory and neuroprotection. 
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2.2 Experimental Procedures 
2.2.1 Primary Mixed Brain Cell Cultures, Chemicals and Treatment 
For a detailed description of experimental procedures, refer to the previous 
chapter.  Briefly, primary mixed hippocampal and cortical cultures were harvested from 
E18.5 C57BL/6J mice. Disassociated cells were randomly plated (6 x 106 for cortical 
cultures and 3 x 106 for hippocampal cultures) on poly-D-lysine (100µg/mL; Sigma-
Aldrich, Missouri) coated 12-well plates containing B27/Neurobasal medium (Invitrogen, 
California) with 0.5mM L-glutamine and 4µg/mL gentamicin.  Cells were maintained in 
a humidified, 5% CO2 atmosphere incubator with a set temperature of 37°C.  Additional 
12-well plates, with poly-D-lysine (100µg/mL) coated coverslips were set aside for 
immunocytochemical purposes.  After 4 days in culture, the media was removed entirely 
and replaced with fresh media; half of the media was changed every 4 days, thereafter, 
until E2 and/or LiCl treatment.  After twelve days in culture, the media was removed 
entirely and replaced with media treated with 10mM LiCl (Sigma-Aldrich, Missouri), 
0.04µM E2 (Sigma-Aldrich, Missouri), or combined E2/LiCl and duration of treatment 
for each group was 48 h.   
  
2.3 Experimental Techniques  
2.3.1 Immunocytochemistry 
Primary mixed cultures were immunolabeled using neurofilament-H (NF-
H) (Upstate, Virginia) and glia fibrillary acidic protein (GFAP) (Sigma-Aldrich, 
Missouri) antibodies.  Cells were fixed for 15 minutes at 4°C with ice-cold 4% 
paraformaldehyde/4% Sucrose/DPBS and permeabilized for 30min at room 
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temperature with 0.25% DPBST (DPBS with 0..25% [v/v] Triton X-100). Non-
specific binding sites blocked with 10% normal goat serum/DPBS overnight at 
4°C.  Primary antibodies were then incubated at room temperature with mouse 
NF-H or GFAP antibodies and visualized using fluorescent-conjugated secondary 
antibodies (directed against the host of the 1° antibody).  Cells were 
counterstained with Hoechst to reveal nuclei, coverslips were mounted on glass 
slides, and sealed with clear nail polish.  Images were captured using a Leica 
Leitz DM RB fluorescent microscope with a Leica DM 500 camera (Leica, 
Bannockburn, IL, USA).  
 
2.3.2 Total RNA Isolation and cDNA Synthesis 
Total RNA was isolated from cultures after treatment with TRIzol reagent 
(GIBCO, California), according to manufacturer’s protocol.  Briefly, cultures were rinsed 
with ice-cold DPBS, TRIzol Reagent (600µL-1mL) was added directly into each well, 
and then homogenized.  Homogenized cells were then transferred to a fresh tube, and 
incubated at room temperature.  Chloroform was added and centrifuged at 6, 700 x g at 
4°C.  Total RNA (aqueous phase) was transferred to a sterile tube and allowed to 
precipitate with isopropanol and glycogen overnight at -20°C.  The RNA was pelleted via 
centrifugation at 6, 700 x g at 4°C, supernatant decanted and RNA pellet was washed 
twice with 75 % ethanol.  Pellets were then air dried and resuspended with DEPC-treated 
water.  The DNA contaminants were removed with the RQ1 DNase kit (Promega, 
Wisconsin).  Total RNA was then reverse transcribed (RT) using SUPERSCRIPTTM II 
RNase H-free reverse transcriptase (Invitrogen, California), according to the 
 45 
manufacturer's protocol.  Briefly, 500ng of total RNA was reverse transcribed with 
0.05µg/µl of Oligo (dT)12-18 at 65°C for 5 minutes.  First strand cDNA was synthesized 
with 5mM MgCl2, 10mM DTT, and 2.5 units Superscript II and incubated at 42°C for 50 
minutes; reaction was terminated at 70°C for 15 minutes.  RNase H (Invitrogen, 
California) was added once the first strand was synthesized to remove any remaining 
RNA by incubated at 37°C for 20 minutes. 
 
2.3.3 Quantitative Real Time RT-PCR 
First strand cDNA was amplified via real time PCR using SYBR Green PCR 
master mix (ABgene, New York), 200-300nM of forward and reverse primers using AB 
7300 qPCR apparatus.  Cycling parameters were set at: 95°C 15s, 57°C or 63°C 30s, and 
extension at 72°C for 30s, for a total of 40 cycles, followed by a final extension at 72°C 
for 10 minutes.  The specific primer pairs were: BDNF: forward primer, 5'-
ATCCAAATATGGCACAGCAA-3; reverse primer, 5'-
TTCTGCCTGAGTTTTGATGC-3'; Bcl-2: forward primer, 5'-
AGGAGCAGGTGCCTACAAGA-3; reverse primer, 5'-GCATTTTCCCA 
CCACTGTCT-3'; ER-α: forward primer, 5'-AAGGGCAGTCACAATGAACC-3; 
reverse primer, 5'-GCCAGGTCATTCTCCACATT-3'; HPRT: forward primer, 5'-
GGAGCGGTAGCACCTCCT-3'; reverse primer, 5'-AATCCAGCAGGTCAGCAAAG-
3'.  All samples were compared with a standard curve comprised of pDNA of HPRT, 
BDNF, Bcl-2, and ER-α generated using TOPO TA Cloning® Kit (Invitrogen, 
California).  Readings were normalized by dividing mRNA starting quantity (SQ) of 
 46 
BDNF, Bcl-2, or ER-α by the house-keeping gene HPRT mRNA SQ; output are in 
picograms (pg) of mRNA.   
 
2.3.4 Statistical Analysis 
Data are presented as the mean ± S.E.M and statistical significances were 
determined by ANOVA followed by Fisher’s least significant difference post-hoc testing.  
Significant differences have a p-value < .05.  All results were obtained from two separate 
experimental procedures with factors and levels randomly determined. 
 
2.4 Results 
2.4.1 Combined E2/LiCl increases factors involved in learning and memory 
I chose to analyze mRNA expression since both estrogen and lithium indirectly 
and/or directly affect genomic responses [23, 31].  Real time RT-PCR results indicate 
that BDNF, ER-α and Bcl-2 mRNA expression significantly differs depending on the 
brain region (p < 0.001) – hippocampal cultures express higher levels of mRNA 
compared with cortical cultures (figures 1A-1C).  I also noted that combined E2/LiCl 
significantly increases (p < 0.05) BDNF and ER-α mRNA expression (figure 1A and 
1C).  Chronic lithium does not affect Bcl-2 expression in glia [8], but I specifically 
wanted to see if a short-term treatment with LiCl (48 h) will alter Bcl-2 gene expression 
in my primary mixed culture predominated by glia.  Expression of Bcl-2 mRNA, 
however, showed no significant differences (p > 0.4) across treatment parameters (figure 
1B).   
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 After a 48 h treatment period E2 alone did not affect BDNF mRNA expression for 
either hippocampal or cortical cultures (figure 1A).  The LiCl and E2/LiCl treatment, 
however, significantly increased hippocampal and cortical BDNF mRNA expression.  In 
cortical cultures, LiCl significantly increased (p < 0.05) BDNF mRNA expression 
compared with Control, but combined E2/LiCl treatment significantly increased (p < 
0.05) BDNF mRNA expression compared with both Control and E2 treated cortical 
cultures (figure 1A).  Hippocampal cultures also displayed this trend, except that LiCl 
also increased BDNF mRNA expression compared with E2 treatment as well (figure 1A).  
There were no significant differences in ER-α mRNA expression for cortical cultures 
across treatments (p < 0.05) (figure 1C).  The E2 treatment did not significantly alter 
hippocampal ER-α mRNA expression when compared with control and, although LiCl 
seemed to increase ER-α mRNA expression this was not a significant increase (figure 
1C).  Combined E2/LiCl treatment, however, significantly increased (p < 0.05) 
hippocampal ER-α mRNA expression after a 48 h treatment period compared with 
Control and E2 treated hippocampal cultures (figure 1C).  These results demonstrate that 
my treatment parameters do not alter Bcl-2 gene expression and that combined E2/LiCl 
treatment increases BDNF and ER-α gene expression but this increase is region-specific 
for ER-α (e.g. increase seen in hippocampal cultures but not cortical cultures).  This 
increased gene expression is significant when compared with Control and E2 treated 
cultures.  Additionally, LiCl treatment only affects BDNF gene expression.  No 
significant differences in gene expression for any markers were detected with E2-treated 
cultures. 
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Figures 1A-C: Real time RT-PCR of BDNF (A), Bcl-2 (B), and ER-α (C) mRNA 
expression.  E18.5 hippocampal (grey bars) and cortical (black bars) primary cell cultures 
were treated for 48 h with 0.04µM E2, 10mM LiCl, combined E2/LiCl, or Control (no 
treatment).  After treatment total RNA was isolated and reverse transcribed.  Expression 
for each gene was normalized using the house-keeping gene HPRT.  The figure denotes 
normalized mRNA expression in picograms (y-axis) and treatment type (x-axis).  *, p-
value < .05 compared with control; #, p-value < .05 compared with E2. 
 
2.5 Discussion 
The immunocytochemical images in figure 2A clearly depict high GFAP 
expression in hippocampal cultures, but still with low NF-H labeling – as noted by the 
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unlabeled surrounding nuclei (figure 2B).  This coincides with findings from the previous  
chapter that these primary mixed brain cell cultures express high levels of glia-specific 
mRNA, but with consistently low levels of neuron-specific mRNA [48].  Also, it is 
noteworthy that harvesting brain cells at E18.5 rather than at E14-E15, along with the 
process of mechanical trituration, promotes viable primary cultures with a predominance 
of glia.  Glia predominate the brain and investigations on how estrogen and lithium affect 
glial molecular mechanisms are essential for developing and providing palliative 
treatment regimes for post-menopausal women.  Glia are known to express similar 
markers as neurons do, such as BDNF, Bcl-2, and ER-α and expression level of these 
markers vary according to neuroanatomical region and developmental stage.  Both BDNF 
[51] and Bcl-2 [7] are highly expressed in hippocampal and cortical regions; however, 
mRNA distribution of ER-α is also expressed in these brain regions but is difficult to 
determine due to low expression level in these brain regions [42].  My data concurs with 
the literature indicating that BDNF, Bcl-2, and ER-α mRNA are expressed in these 
hippocampal cultures and cortical cultures, but higher expression is noted in hippocampal 
cultures (figures 1A-1C).  
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Figures 2A-2B: Immunocytochemical images of hippocampal cultures labeled with 
GFAP (A; 200X) and; NF-H (B; 400X) antibodies (green). All nuclei are labeled with 
Hoechst stain (blue).  Image color quality and gamma adjustments were made using 
Adobe Photoshop CS. 
 
I note no significant differences in Bcl-2 gene expression across cultures and all 
treatment types (figure 1B).  This absence coincides with results obtained from chronic 
lithium treated neuronal and glial cell lines [8].  Studies do indicate that E2 increases Bcl-
2 expression in primary neuronal cultures from prenatal rat hippocampus, specifically 
with the concentration and treatment period used in my study [50].  Since I used cultures 
expressing high GFAP levels (figure 2A), the E2 concentration Wu et al. [50] used must 
not affect glia Bcl-2 expression – solely at the transcriptional level and under my 
experimental parameters, though (figure 1B).  Wu et al. [50] explains that the molecular 
mechanisms that underlie E2 up-regulating Bcl-2 is mediated through ER-α interactions 
within the Akt pathway.  One potential explanation for my results is the ER-α/Akt 
pathway is highly dependent on PELP1 [4] and PELP1 is expressed at lower levels in glia 
[24]; there are caveats of molecular processes that may be at play, though.   
 
In the previous chapter, I note that in E2-treated cultures LiCl reduces NMDA 
subunit NR1 mRNA expression [48].  In the present study, E2 has an additive effect in 
LiCl-treated cultures on BDNF and ER-α mRNA expression, however, E2 alone does not 
significantly alter BDNF or ER-α expression (figure 1A and 1C).  Lack of altering 
mRNA BDNF or ER-α expression may be explained by the plasticity of estrogen-
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mediated signaling pathways.  Direct genomic effects are classically mediated by 
estrogen bound ERs, one specific target is NMDA subunit promoter regions [49] and 
transcriptional properties of ERs are facilitated by GSK-3β – a pathway attenuated by 
lithium [32].  Attenuation by lithium could explain findings from the previous chapter, 
but some other mechanism must be at play to explain my present findings.  Estrogen 
mediates indirect genomic effects by binding to ERs and non-ERs such as G-protein 
coupled receptor, GPR30 [31, 38], which is shown to be expressed in rat brain [3] and 
activate adenylyl cyclase resulting in cAMP production [38].  Production of cAMP 
ultimately leads to the activation of the transcription factor cAMP response element 
binding protein (CREB) [22].  Lithium is a well known facilitator of CREB DNA binding 
properties by selectively inhibiting GSK-3β, a CREB attenuator [14], and BDNF gene 
expression is mediated by CREB [17, 26].  These indirect genomic effects mediated by 
estrogen may be facilitated by lithium, thereby increasing BDNF mRNA expression 
(figure 1A); however, further investigation is needed to elucidate the upstream molecular 
pathways involved using my experimental parameters.   
 
The literature is dichotomous on whether lithium increases BDNF levels in the 
hippocampus or not.  Studies show that rats chronically treated with lithium for 2 and 4 
weeks increase BDNF expression in their hippocampus [11], but Hammonds and Shim 
[17] demonstrate that a 4 week lithium treatment does not alter BDNF levels specifically 
in rat CA1 region of the hippocampus.  There may be some developmental differences, 
since Fukumoto et al. [11] used younger rats compared with Hammonds and Shim [17].  
Additionally, Hammonds and Shim [17] showed BDNF expression is specific to 
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neuroanatomical regions, since they reported that lithium did increase BDNF expression 
in the dentate gyrus.  In my study, LiCl increased BDNF gene expression for both culture 
types (hippocampal and cortical), specifically compared with Control (figure 1A), but the 
literature states that astrocytic BDNF expression is not affected by lithium [16].  Guo et 
al. [16] used neonatal rat primary cortical astrocytic cultures showing no effect by lithium 
on BDNF expression, but lithium does increase BDNF among rat cortical neurons [18] 
and my results on ER-α and BDNF mRNA expression may be influenced by the low 
neuronal population in my primary mixed cultures (figure 2B; [48]).  Additionally, Guo 
et al. [16] treated their cultures for only 20 h which might indicate a temporal difference 
in lithium treatment and BDNF expression.  But the interesting note is that in the Guo et 
al. study, these lithium-treated primary astrocytic cultures also expressed increased GSK-
3β inhibition [16]. 
 
Results indicate that although E2 or LiCl treatment does not significantly alter 
ER-α mRNA levels, I note a significant additive effect by E2 in LiCl-treated 
hippocampal cultures (figure 1C) that express high GFAP immunoreactivity (figure 2A).  
Under conditions of neuronal damage, ER-α expression increases among neonate rat 
cortical astrocytes, mediated by E2, and this increase aids neuronal damage [6].  Cortical 
ER-α mRNA expression was not affected by my treatment parameters, though (figure 
1C).  Cortical cultures did express higher glia-specific mRNA than hippocampal [48] and 
I report in the present study that primary hippocampal cultures show NF-H perikaryon 
accumulation (figure 2B), which is indicative of neuronal apoptosis [28].   
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Recent studies using neuronal cell lines show that ER-α gene expression has an 
E2 dose dependency – reducing ER-α gene expression within 16 h treatment of 0.1µM 
E2 [36].  Other studies indicate that ER-α increases in neonatal rat hippocampus with E2 
treatment [40].  ER-α also raises developmental considerations since ER-α expression in 
rat brain is high during prenatal day 9, declines then increases at neonate stage and then 
declines again with age [47]; this occurs in both the hippocampus and cortex [13].  
Cultures used in this study are from embryonic mouse brain (E18.5) and this 
developmental factor may account for differences noted in other publications, but I show 
no significant differences in ER-α mRNA expression with E2 or LiCl individual 
treatment (figure 1C).  
 
Studies show that combined estrogen and lithium affect the dopamine pathway, a 
pathway associated with many neurodegenerative diseases [34, 43].  Stereotyped-
behavior is increased with apomorphine, a dopaminergic agonist, in ovariectomized rats 
after discontinuing chronic treatment of estrogen; but this increase in stereotyped-
behavior is diminished with lithium [10].  Additionally, ovariectomized rats treated with 
combined E2 and LiCl show greatly decreased dopamine levels, but show higher levels 
of serotonin and dopamine metabolites in the brain [33].   Results presented in this 
chapter are generated and interpreted at the transcriptional level but these results indicate 
that some molecular mechanism is being altered as a result of my treatment paradigm.  
Many brain cell signaling pathways are facilitated by both estrogen and lithium and both 
seem to affect similar pathways.  One common element that both estrogen and lithium 
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possess is an interaction with GSK-3β since lithium affects estrogen receptor–mediated 
cell signaling via GSK-3β inhibition [32].  Evidence showing that combined estrogen and 
lithium affect GSK-3β and dopamine pathways postulate some underlying interaction 
between estrogen and lithium that affect brain cell signaling pathways.  Knowledge on 
how estrogen and lithium interact at the molecular level will contribute to providing 
proper treatment regiments for women undergoing ERT while displaying symptoms of 
depression.   
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CHAPTER III 
Lithium Enhances Episodic Memory and the Expression of Factors Involved in Learning, 
Memory and Anti-Apoptosis in Estrogen-Deficient Mice 
 
Abstract  
The hippocampus and cortex are areas of the mammalian brain that are involved 
in learning and long-term memory, respectively. Also, there is a tendency for learning 
and memory to decline in adult women during peri- and post-menopausal periods.  Both 
estrogen and lithium affect learning and memory processes and both of these agents may 
be prescribed to post-menopausal women; however, the literature shows that hormone 
therapy is correlated with an increased incidence of breast cancer.  I hypothesized that in 
estrogen-deficient mice lithium alone will enhance behavioral task performance, and in 
the brain, increase expression of factors involved in learning and memory.  My study 
used bilaterally ovariectomized (bOVX) C57BL/6J mice treated for one month with 
14.2mM lithium chloride (LiCl) in their drinking water.  Results indicated that LiCl-
treated bOVX mice enhanced their performance in an object recognition task (ORT) 
compared with non-treated bOVX.  Enhanced performance in ORT led me to examine in 
the hippocampus and cortex, expression of mRNA and related proteins involved in 
learning, memory and neuroprotection.  Gene expression of these factors are increased in 
the cortex of LiCl-treated bOVX mice, but not in the hippocampus, compared with non-
treated bOVX mice.  A glutamate receptor subunit and neurotrophic factor protein 
expression increased in the hippocampus of LiCl-treated bOVX mice compared with 
non-treated bOVX mice.  Additionally, increased protein and mRNA expression 
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coincided with increased inhibition of a kinase involved in attenuating expression of 
markers relevant to learning, memory and neuroprotection.  I believe my study may be 
useful in developing palliative therapies that use lithium as a treatment for cognitive 
decline associated with estrogen-deficiency (e.g. post-menopause). 
 
3.1 Introduction  
A lack of circulating estrogen during peri-menopause is correlated with cognitive 
decline [29].  Hormone therapy is usually prescribed during peri- and post-menopause, 
but increased breast cancer incidences are reported for women undergoing hormone 
therapy [31].  Scientific investigations do indicate that estrogen-mediated 
neuromechanisms enhance synaptic plasticity [25], reduce apoptotic activity in cortical 
neurons [21], regulate brain derived neurotrophic factor (BDNF) [40], and facilitate 
transcription factor activation such as cyclic adenosine monophosphate (cAMP) 
responsive element binding protein (CREB) [27].  Estrogen stimulates molecular 
processes involved in learning and memory; however, hormone therapy does not improve 
cognitive decline during menopause, specifically episodic memory [20].  Ovariectomized 
(OVX) and estrogen receptor-α (ER-α) knockout mice perform poorly on hippocampal-
dependent behavioral tasks indicating that normal circulating estrogen and ER-α 
expression influence cognitive-behavioral performance levels [11].  Co-localization of 
ER-α and BDNF are noted in pyramidal cells of the hippocampus, and estrogen 
influences BDNF expression [40].  Ligand binding of BDNF to tyrosine receptors 
initiates a signaling cascade that results in activating CREB [3], increasing synaptic 
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plasticity [43], and facilitating CREB-mediated gene expression via N-methyl-D-aspartate 
receptor (NMDAR) signaling pathways [47].   
 
Lithium is commonly prescribed for bipolar disorder and schizophrenia [10], but 
lithium also affects several molecular pathways via glycogen synthase kinase-3beta 
(GSK-3β) inhibition [24].  Inhibition of GSK-3β  reduces apoptotic activity [22], 
increases neurotrophic factors [2], and facilitates CREB’s response element binding [15, 
33].  Though the mechanism remains elusive, the literature states that lithium inhibits 
GSK-3β through indirect and direct mechanisms.  Indirectly, lithium promotes protein 
kinases that inhibit and may simultaneously inhibit phosphatases that activate GSK-3β  
[24].  Lithium directly inhibits GSK-3β by acting as a competitive inhibitor of 
magnesium, magnesium being co-factor for ATP in GSK-3β activation [36]. Aside from 
lithium’s inhibitory action on GSK-3β, lithium acts as neuroprotectant by indirectly 
influencing NMDAR signaling.  Lithium decreases NMDAR-mediated excitotoxicity by 
reducing phosphorylation/activation of Src tyrosine kinases thus inhibiting NMDAR 
subunit signaling pathways [18].  The neuroprotective properties of lithium are also 
marked by increased levels of the anti-apoptotic agent B-cell lymphoma/leukemia-2 (Bcl-
2) and BDNF [5].  Estrogen also facilitates Bcl-2 expression by the CREB activation 
pathway and by indirectly interacting with NMDAR [50]. 
 
Estrogen and lithium influence similar signaling transduction pathways; 
specifically facilitating molecular signaling pathways involved in learning and memory 
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[15, 27].  Chapter one experimental data showed that combined estrogen and lithium 
chloride (LiCl) treatment reduces mRNA expression of NR1, a critical subunit of 
NMDAR, in primary mixed brain cell cultures, predominated by glia [42], indicating 
interaction between estrogen and lithium in genetic expression.  A former master’s 
degree graduate from the laboratory of my advisor, Dr. Ophelia I. Weeks, showed that 
14.2 mM LiCl in drinking water maintains a sub-therapeutic plasma level of lithium at 
about 0.2 mM and facilitates enhanced performance in spatial and non-spatial memory 
tasks (unpublished data).  In the present study I hypothesized that LiCl-treated estrogen-
deficient mice will perform better in an object recognition task (ORT) by altering 
mRNA/protein expression of factors involved in learning, memory and neuroprotection 
in the hippocampus and cortex.  To test my hypothesis I treated bilaterally OVX (bOVX) 
C57BL/6J mice with 14.2 mM LiCl for 1 month.  Results presented in this chapter 
indicate that LiCl treatment enhances ORT performance in bOVX mice and this 
enhancement coincides with an increase in factors involved in learning, memory and 
neuroprotection.   
 
Typically, women undergo natural menopause by their late 40s to early 50s and 
estrogen replacement therapy (ERT) is commonly prescribed peri- and post-menopause.  
Post-menopausal women on ERT may be at risk, since there is increased incidences of 
lobular carcinoma in women undergoing ERT [31].  Selective estrogen receptor 
modulators (SERMs) provide an alternative to ERT but studies show that SERMs do not 
improve cognitive functioning [30, 34].  Therefore, an alternative therapy for peri- and 
post-menopausal women is wanting.  The present study will contribute data to the 
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literature on lithium’s potential as a therapeutic agent for enhancing cognitive function 
during a period of estrogen-deficiency.   
 
3.2 Experimental Procedures 
3.2.1 Subjects, Surgery and Treatment  
C57BL/6J female mice (n = 20) were purchased from Jackson Laboratories.  
Animals were kept in an environment of 20-22°C temperature, 60% humidity, within 
polycarbonate transparent cages (26.7cm X 20.6cm X 14cm) on a 12-hour day-night 
cycle with free access to water and food.  The Institutional Animal Care and Use 
Committee approved all experiments (08-017).   
 
At 4.5 months of age mice were anesthetized with ether, weighed, and both 
ovaries were removed surgically.  Mice were positioned dorsal side up and for each 
surgical procedure, parallel to the long axis of the animal’s body, an incision ¾ cm in 
length was made ½ cm from the hip area.  The fallopian tube was located bilaterally and 
both ovaries were removed.  Treatment with 14.2mM LiCl + 0.9% Saline in their 
drinking water began at 5 months of age for 1 month; LiCl at 14.2mM maintains lithium 
blood content at a sub-therapeutic range (< 0.5 mM) [37].  The control group received 
only 0.9% Saline in their drinking water.  All animals were divided into four groups 
(lithium-treated bOVX and Sham; saline-treated bOVX and Sham).  Mice were handled 
for 15-30 s weekly and weighed weekly.  After a one-month treatment period, mice were 
subjected to a cognitive-behavioral task (e.g., ORT).  
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3.2.2 Object Recognition Task (ORT), Thigmotaxis and Velocity 
Studies using ORT indicate that animals habituate to an object and when 
subsequently introduced to a different, novel object these animals will spend greater 
lengths of time with the novel object [32].  In addition, ORT is known to be highly 
dependent upon the hippocampus [44, 48] and is a form of episodic memory.  The ORT 
were performed in an arena measuring 121 cm in diameter, with a depth of 22cm.  The 
arena was painted white and the flooring covered with bedding material.  Two strips of 
Velcro, 60cm apart were placed on the bottom of the arena to secure each object.  There 
were three objects in total: two oval/egg-shaped objects (Old) and one pyramid object 
(New).  All objects were of the same color and size, made of the same material, by the 
same manufacturer (Playskool®).  All objects were wiped with 95% ethanol between 
trials.  Twenty-four hours (24 h) prior to each treatment regime, 3-5 experimental mice 
were allowed to run freely in the empty arena (no objects) for 30 min to introduce 
olfactory cues to the testing arena.  After olfactory habituation, each mouse was 
individually exposed to two identical objects (egg shaped), for ten minutes (priming).  
After priming, the subject was rested for thirty minutes and then tested on novel object 
recognition for ten minutes.  During this portion of the test, one of the two old objects 
was replaced with a new pyramid object (positioning of objects was randomized).  These 
last ten minutes were videotaped using a Panasonic digital camera and analyzed with the 
tracking system EthoVision XT (version 5.0 Noldus Information Technology, Leesburg, 
VA) to measure ORT, thigmotaxis to measure anxiety and velocity to measure speed.  
Parameters for ORT were measured when the subject came within 5cm of the new object, 
and/or investigated the new object.  Measurements were calculated and presented as a 
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percentage, based on the following calculation, the novel object/(novel object + old 
object).  Thigmotaxis measures anxiety displayed by the experimental mice.  Anxiety was 
characterized as time spent 5cm from the edge of the arena, defined as the thigmotactic 
zone, distinguishable from the ORT zone, the inner area with a diameter of 116cm (the 
total diameter being 121cm).  Velocity was measured as the average speed (cm/sec) of 
experimental mice.  A baseline measurement for each parameter (ORT, thigmotaxis and 
velocity) was taken using non-experimental mice (n = 3). 
 
3.2.3 Uterine and Bone Weight   
All mice were anesthetized under ether and were then cervically dislocated.  
Brains, uteri, femora and humeri were removed from each experimental mouse.  Each 
uterus was weighed and inspected to assure complete removal of ovaries during bOVX 
surgery.  Bones were dried at 70°C for 24 h and then weighed.    
 
3.2.4 Total RNA Isolation and Reverse Transcription (RT)   
After ORT, total RNA was isolated from brain tissue using TRIzol reagent 
(GIBCO, California), according to manufacturer’s protocol.  Briefly, brains were 
removed from each subject, the cortex and hippocampus of each hemisphere were 
isolated under a dissecting microscope, weighed, and rinsed with Dulbecco’s Phosphate 
Buffer Saline (DPBS).  A 1:10 weight TRIzol reagent was added then homogenized with 
an IKA homogenizer (speed 5 for 10 s).  Chloroform was added and centrifuged at 
12,000 x g for 15 min at 4°C.  After phase separation total RNA (aqueous phase) was 
collected and the protein (phenol phase) was stored at -80°C for further processing (see 
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Protein isolation and Western Blot section).  Total RNA was then precipitated with 
isopropanol and RNA was pelleted via centrifugation.  Total RNA pellet was washed 
with 75 % ethanol and then resuspended in DEPC-treated water.  To remove any DNA 
containments RQ1 DNase kit (Promega, Wisconsin) was used.  Aliquots of samples were 
used for concentration and purity quantification using absorptions at 260 nm and 280 nm.  
 
First strand cDNA synthesis was performed using SUPERSCRIPTTM III RNase 
H-free reverse transcriptase (Invitrogen, California), according to manufacturer's 
protocol.  Briefly, 3 µg of total RNA was reverse transcribed with 0.05µg/µl of Oligo 
(dT)20 at 65°C for 5 min.  First strand cDNA was synthesized with Superscript III/RNase 
OUT Enzyme mix and incubated at 50°C for 50 min; reaction was terminated at 85°C for 
5 min.  RNase H (Invitrogen, California) was added once first strand was synthesized to 
remove any remaining RNA.  RNase H was incubated at 37°C for 20 min. Samples were 
stored at -20°C until further processed. 
 
3.2.5 Quantitative Real Time RT-PCR   
First strand cDNA was amplified via real time PCR using SYBR Green PCR 
master mix (ABgene, New York), 200-300nM of forward and reverse primers using AB 
7300 Real Time PCR system.  Cycling parameters were set at 95°C for 30 s, 57°C - 63°C 
for 30 s, and extension at 72°C for 30 s, for a total of 40 cycles, followed by a final 
extension at 72°C for 10 min.  The specific primer pairs were: ER-α: forward primer, 5'-
AAGGGCAGTCACAATGAACC-3; reverse primer, 5'-
GCCAGGTCATTCTCCACATT-3'; NMDAR subunit NR1: forward primer, 5'-
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ACTCCCAACGACCACTTCAC-3; reverse primer, 5'-
GTAGACGCGCATCATCTCAA-3'; Bcl-2: forward primer, 5'-
AGGAGCAGGTGCCTACAAGA-3; reverse primer, 5'-GCATTTTCCCA 
CCACTGTCT-3'; BDNF: forward primer, 5'-ATCCAAATATGGCACAGCAA-3; 
reverse primer, 5'-TTCTGCCTGAGTTTTGATGC-3'.  The endogenous control was 
HPRT: forward primer, 5'-GGAGCGGTAGCACCTCCT-3'; reverse primer, 5'-
AATCCAGCAGGTCAGCAAAG-3'.  All samples were compared with a standard curve 
comprised of pDNA generated using TOPO TA Cloning® Kit (Invitrogen, California).  
Readings were normalized by dividing interest gene number of copies by the house-
keeping gene (HPRT) number of copies; output is the ratio mRNA number of copies 
(described in the previous chapters as starting quantity).  
 
3.2.6 Protein Isolation and Western Blot   
Protein isolation from TRIzol after DNA precipitation was performed according 
to manufacturer’s protocol.  Briefly, protein was precipitated with isopropanol, 
centrifuged at 10000 x g for 10 min, and pellet washed several times with 0.3M guanidine 
hydrochloride/95% ethanol.  Pellet was resuspended in 1% SDS and stored at -20°C until 
further processing.  A Bradford assay was used to determine protein concentration of 
cortical and hippocampal lysates and calculated for 20 µg/lane.  Samples were diluted in 
non-reducing sample buffer (0.3 M Tris-HCl [pH 6.8]; 2% SDS; 10% Glycerol; 0.01% 
bromophenol blue) and boiled at 100°C for 5 min.  Protein samples were separated by 
molecular weight with an 8%-16% SDS polyacrilamide gel and transferred onto a 
nitrocellulose membrane using XCell II Blot Module (Invitrogen, California).  Non-
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specific binding sites were blocked overnight at 4°C with 5% non-fat dry milk in TBST 
(TBS with 0.1% [v/v] Tween-20) and immunolabeled at room temperature for 1.5 h using 
antibodies against: BDNF (Santa Cruz Biotechnology, California) and; NMDAR subunit 
NR1, Phospho-CREB (serine 133), and Phospho-GSK-3β (serine 9) (Cell Signaling, 
Massachusetts).  Membrane was then incubated at room temperature for 1 h with 
secondary horseradish peroxidase-conjugated antibodies (directed against the host of the 
1° antibody); signal enhanced with LumiGLO (Cell Signaling, Massachusetts) and 
developed/visualized using x-ray film.  Membranes were stripped with 0.2 M Glycine 
(pH 2.5) and 0.1% (v/v) Tween-20 and labeled with anti-actin (Sigma-Aldrich, MO) – 
used as a loading control.  Images of x-ray films were scanned using a CanoScan Lide 30 
scanner (Canon). 
 
3.2.7 Statistical Analysis   
The data are presented as mean±S.E.M and statistical significance is determined 
by ANOVA followed by LSD post-hoc procedure.  Significant differences have p-values 
< 0.05.   
3.3 Results 
3.3.1 Removal of ovaries from mice resulted in weight gain   
During pre-bOVX all mice weighed on average 22.0g.  Throughout post-bOVX 
and treatment period, mice were handled and weighed weekly prior to ORT.  The average 
weekly weight showed that both Sham groups (non-treated and LiCl-treated Sham) 
roughly weighed the same (23.6g); however, LiCl-treated bOVX (25.5g) weighed less 
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than non-treated bOVX (27.0g).  Statistical analyses on weekly weight indicated that 
non-treated bOVX significantly weighed more (p < 0.05) than non-treated Sham and 
LiCl-treated Sham during week 1, 2, 4, and 5  – week 3 the significant difference lies 
solely compared with non-treated Sham (figure 1).  Weight gain for LiCl-treated bOVX 
mice fluctuated since weight gain was not apparent during week 3 and 5 in LiCl-treated 
bOVX compared with both Sham groups – there was also no difference during week 1 
when LiCl-treated bOVX were compared with LiCl-treated Sham (figure 1).  I also 
monitored the daily volume intake of the treatment (or control) that indicates the average 
intake of LiCl-treated water (21.7mL/day/mouse) was slightly less than saline treated 
water (24.4mL/day/mouse), but this difference was not significant (p > 0.05).   
 
3.3.2 An increase of episodic memory by LiCl in estrogen-deficient mice   
Cognitive decline is a common characteristic of estrogen-deficiency as measured 
by behavioral tasks [11].  Figure 2A shows that non-treated bOVX animals showed 
decreased performance in ORT compared with the baseline group and the other three 
experimental groups.  Statistical analysis of ORT indicated that LiCl-treated bOVX mice 
showed a significant increase (p < 0.05) in novel object recognition performance when 
compared with non-treated bOVX (figure 2A).  The LiCl-treated Sham group showed a 
13% increase in novel object recognition compared with non-treated bOVX, but this 
proved to be non-significant (p > 0.05).  I also measured thigmotactic behavior and 
velocity showing that experimental mice displayed less anxiety (figure 2B) and speed 
(figure 2C), respectively, compared with baseline.  These parameters, however, showed 
no significant changes across treatment groups.  
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1. 
 
 
 
 
 
 
 
 
 
Figure 1. Weekly weight of experimental mice. *, significant increase compared to 
bOVX; #, significant increase compared to bOVX + LiCl. 
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Figures 2A-2C. Performance level on ORT (A), thigmotaxis (B) and velocity (C) using 
EthoVison XT (see Experimental Procedures section).  Baseline performance is indicated 
by the black line across the graphs. *, significant increase performance compared with 
non-treated bOVX.  
 
 
3.3.3 Bones and Uteri   
Osteoporosis and uterine atrophy are pathological characteristics of estrogen-
deficiency [13].  I analyzed dry bone weight from experimental mice and noted no 
significant differences between non-treated and LiCl-treated groups or between bOVX 
and Sham (figures 3A).  Uterine weight was significantly less in bOVX (non-treated and 
treated) compared with Sham (non-treated and treated), but no significant differences 
between treatment groups were noted (figures 3B).   
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Figures 3A-3B. Bone (A) and Uterine weight (B). *, significant increase compared to 
bOVX; #, significant increase compared to bOVX + LiCl. 
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3.3.4 Altered levels of Bcl-2, BDNF, ER-α and NR1 by LiCl in estrogen-deficient mice   
Since LiCl increased episodic memory in bOVX mice according to ORT analysis 
(figure 2A), I hypothesized this enhanced performance was caused by increased 
expression of mRNA and proteins involved in learning, memory, and anti-apoptotic 
activity in the brain.  Figures 4A-4D shows that overall mRNA expression of ER-α, NR1, 
Bcl-2 and BDNF differed between the hippocampus and cortex – ER-α and NR1 
expressed higher in the cortex, and Bcl-2 and BDNF expressed higher in the 
hippocampus.  Statistical analysis suggest LiCl-treated bOVX mice show significant 
increases (p < 0.05) in cortical mRNA expression of these genes, but with no significant 
differences in hippocampal mRNA expression across treatment groups (figures 4A-4D).   
 
Once bound by estrogen, ER-α facilitates NMDAR subunit expression via 
response element binding [46] and ER-α response element binding is attenuated by 
lithium [28].  LiCl-treated bOVX mice show significantly enhanced (p < .05) cortical 
ER-α mRNA compared with non-treated bOVX and Sham (figure 4A).  Cortical NR1 
mRNA of LiCl-treated bOVX significantly increased (p < .05) compared with Sham and 
LiCl-treated Sham, but not in non-treated bOVX (figure 4B).  Lithium influences Bcl-2 
activity through BDNF signaling cascade [38], a signaling pathway that is also affected 
by estrogen [27].  Figures 4C and 4D show that LiCl treatment significantly elevates Bcl-
2 and BDNF cortical mRNA levels (p < .05) in bOVX mice compared with non-treated 
bOVX, Sham and LiCl-treated Sham.  Cortical BDNF mRNA levels are also significantly 
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higher (p < 0.05) in Sham and LiCl-treated Sham compared with non-treated bOVX 
(figure 4D). 
 
Although the hippocampus showed no increase in genetic expression I wanted to 
see if protein levels were altered.  I used TRIzol reagent to obtain total RNA and protein 
from each case study to avoid any discrepancies that might occur if RNA and protein 
were isolated from different subjects (see Experimental procedures). I analyzed NR1and 
BDNF expression and noted that in the hippocampus of LiCl-treated bOVX mice NR1 
and BDNF protein expression increased compared to non-treated bOVX mice (figures 5A 
and 5B).  An increase in NR1 was also noted in LiCl-treated bOVX mice compared with 
both Sham groups (figure 5A) – this increase was not noted for BDNF, though (figure 
5B). 
 
3.3.5 Phosphorylated GSK-3β levels are altered by LiCl  
Lithium facilitates CREB transcriptional properties by inhibiting GSK-3β activity 
[15].  I hypothesized that LiCl-treated bOVX mice will express in their hippocampus 
higher levels of phosphorylated CREB (pCREB) at serine 133 (CREB’s activation 
residue) and higher levels of phosphorylated GSK-3β (pGSK-3β) at serine 9 (GSK-3β’s 
inhibitory residue).  I found that in LiCl-treated bOVX mice pGSK-3β increased 
compared to non-treated bOVX mice (figure 6B), but this increase was not apparent for 
pCREB (figure 6A).  No differences were found in levels of pGSK-3β in LiCl-treated 
bOVX mice compared with both Sham groups, though (figure 5B). 
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Figures 4A-4D. Hippocampal and cortical mRNA expression for ER-α (A), NR1 (B), 
Bcl-2 (C), and BDNF (D) using quantitative RT-PCR.  *, significant increase compared 
to non-treated bOVX; #, significant increase compared to non-treated Sham; †, 
significant increase compared to LiCl-treated Sham. 
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Figures 5A-5B. Hippocampal protein expression of NR1 (A) and BDNF (B).    
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Figures 6A-6B. Hippocampal phosphorylated protein expression of pCREB at serine 133 
(A) and pGSK-3β at serine 9 (B).  
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3.4 Discussion 
In the laboratory of Dr. Ophelia I. Weeks, my advisor, a former graduate student 
performed a study treating male C57BL/6J mice using the same LiCl dosage in the 
current study (14.2mM LiCl).  Treating male mice with this LiCl dosage increased their 
performance in a Morris Water Maze and ORT over a 5 month period (unpublished data).  
Atomic absorption spectroscopy analyses of lithium content showed that treating mice 
with 14.2mM LiCl in their drinking water maintained a sub-therapeutic level of about 
0.2mM lithium (figure 7A).  A therapeutic range is 0.6-1.5mM [37].  I later assayed 
serum samples from these male LiCl-treated mice for the dominant form of estrogen, 
17β-estradiol (E2) and noted that these animals showed elevated E2 plasma-content 
(figure 7B).  That lithium could increase E2 content in these male mice is consistent with 
other studies that showed a lithium-related E2 increase in female rats [1]. 
 
In the present study, I specifically wanted to analyze the affect of 14.2mM LiCl 
on episodic memory in estrogen-deficient mice since this form of memory is 
compromised in women during post-menopause periods [20].  A lack of circulating 
estrogen results in uterine atrophy, and I clearly showed that uterine weight of bOVX 
mice is significantly lower compared with Sham mice (figure 3B).  Interestingly, lithium 
is reported to increase cell proliferation and hyperplasia in murine uteri [16].  
Furthermore, lithium treatment increases human [6] and murine [51] bone density.  But in 
the current study, I did not find increases in uterine weight or bone density with lithium 
treatment (figure 3A & 3B).  Treatment duration and developmental stage of 
experimental animals may account for these differing results since Clément-Lacroix et al. 
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Figure 7A-7B.  Lithium and Estradiol blood content of C57BL/6J male mice. Atomic 
absorption spectroscopy depicting lithium-blood content of (mM) (A), and enzyme linked 
immunosorbent assay depicting estradiol plasma content (ng/mL) (B).  
 
 
The ORT performance was not significantly different in LiCl-treated Sham mice 
compared with non-treated Sham, but when estrogen is diminished (e.g. bOVX) LiCl 
significantly compensated for episodic memory loss compared with non-treated bOVX 
mice (figure 2A).  Lithium does improve consolidating fear memories mediated by β-
catenin and processed by the amygdala [26] and studies show that lithium improves 
spatial memory in rats treated with an inhibitor of spatial memory [39].  Additional 
studies show that stereotypic behavior induced by apomorphine increased in OVX rats 
compared with non-bOVX, but no difference occurred in stereotypic behavior when these 
groups were treated with lithium [45].  Similar studies showed that lithium decreased 
stereotypic behavior induced by apomorphine in bOVX rats after an abrupt halt of long-
term estrogen treatment, but non-estrogen treated bOVX rats did not display this decrease 
[7].  In my study, lithium may be compensating molecular mechanism by enhancing 
estrogen-mediated signaling in a system with reduced levels of this hormone (e.g., 
bOVX).  Jope [23] proposes a bimodal model for lithium, indicating that lithium 
regulates positive and negative cell signaling mechanisms by stabilizing extreme and/or 
minimized levels of integral factors involved in these cell signaling mechanisms.  
Lithium’s bimodal mechanism may facilitate estrogen-mediated brain cell signaling in an 
estrogen-deprived system.  I show that in bOVX mice LiCl significantly increases 
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episodic memory and that this coincides with an increase in genes and proteins involved 
in learning, memory and neuroprotection (figures 4A-4D and 5A-5B).   
 
In learning or experiencing novel stimuli, recent information is processed in the 
hippocampus affecting synaptic connectivity within this brain region.  Increased exposure 
to this novel stimuli causes synaptic connections to form between hippocampal and 
cortical neurons and further exposure causes cortical neurons to form cortico-cortical 
neuronal connections [8].  These cortico-cortical neuronal formations are attributed to 
long-term memory as opposed to the hippocampus that retains recent information [8].  In 
chapter three, I used an ORT to analyze episodic memory and how lithium may affect 
this form of memory.  Episodic memory is a form of declarative memory, categorized as 
long-term memory [41].  Studies do show that mice spend more time with a novel object 
than an older one [32].  In this chapter, an increased exposure to a once novel object – 
e.g. the priming portion of the ORT (see Experimental procedures) – will be retained in 
the mouse’s long-term memory (retention of any stimuli beyond 30 s is considered long-
term memory) causing the mouse to investigate the novel object.  My results show that in 
estrogen deficient mice, LiCl enhances the ability to distinguish the old object versus the 
novel one, thereby spending more time investigating the novel object (figure 2A).  
According to Hebb’s theory, hippocampal-cortical and cortico-cortical connections 
display phase sequences, which are cell assemblies possessing a functional relationship 
and responsible for organizing behavior [19].   
. 
 
 86 
 Synaptic connectivity is facilitated by BDNF and functional NMDA receptors 
(heteromeric structures containing the critical subunit NR1) are required for neuronal 
communication.  An increase in cortico-cortical neuronal connections may explain my 
results since I noted higher levels of mRNA expression in the cortex than in the 
hippocampus of LiCl-treated bOVX mice (figures 4A-4D), specifically factors involved 
in learning and memory.  Lithium does have a temporal range of action since the 
literature shows that expression of BDNF and its receptor is dependent on acute rather 
than chronic lithium treatment [12]. 
 
Protein analysis indicate that LiCl compensated expression of hippocampal NR1 
(figure 5A) and BDNF (figure 5B) in a system deprived of estrogen (e.g. bOVX).  The 
increase in hippocampal NR1 and BDNF expression coincided with higher levels of 
inhibited GSK-3β (figure 6B).  Attenuation of CREB’s transcriptional properties are 
caused by GSK-3β [15].  Although I noted no changes in the activated form of CREB 
(figure 6A), I can postulate that in the hippocampus CREB’s transcriptional properties 
are not attenuated as much in LiCl-treated bOVX mice compared with non-treated bOVX 
mice – this is also noted by the increased cortical genetic expression as well (figures 4A-
4D and figures 5A-5B).  It is worth noting that CREB does facilitates BDNF, Bcl-2 and 
NR1 [4, 17, 35]; additionally ER-α mediates CREB activation [27] and ER-α is also 
responsible for NMDA receptor subunit transcription [46] – and lithium potentiates 
CREB activity [15].  
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 (Protein analysis of cortical samples would augment this study but complications 
arose when isolating cortical protein from TRIzol.  There are a number of factors that 
fostered these complications including nucleic acid and guanidine contamination which 
could have formed aggregates that attenuated protein migration during electrophoresis or 
protein degradation.  Efforts to remedy these problems are underway). 
 
In addition to my experimental design, I noted that although experimental mice 
did not display anxiety, they significantly displayed less anxiety compared to baseline 
mice (figure 2B).  This observation provides a better system for obtaining reliable 
behavioral data since the experimental mice were handled weekly (see Methods and 
Approach) and baseline mice were not – indicating that consistent contact with these 
mice reduces anxiety during behavioral testing.  Studies do show that mice perform better 
on behavioral task in enriched environments [9] and habituating to human contact 
provides similar improvements since experimental mice used in my study (with the 
exception of non-treated bOVX) performed better in the ORT (figure 2A).  Studies do 
show that OVX does cause cognitive impairment in mice [11] and may be the reason why 
non-treated bOVX mice performed lower than baseline. 
 
The benefits of ERT are debatable since studies have shown that ERT reduces the 
development of neurodegenerative diseases and improves cognitive decline [14, 49]; but 
these findings have been recently challenged [20].  It seems that the risk of ERT 
outweigh its benefits, since ERT also increases breast cancer [31].  Estrogen is essential 
for normal brain function by facilitating factors involved in learning, memory and 
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neuroprotection.  An alternative therapy that mimics the beneficial aspects of estrogen, 
without the harmful effects will serve as a better treatment for post-menopausal women.   
I describe in this chapter that in mice deprived of estrogen (bOVX), lithium enhances 
episodic memory (figure 2A), increases factors involved in learning memory and 
neuroprotection (figures 4A-4D and 5A-5B), and increases the inhibitory state of a kinase 
(figure 6B) that attenuates learning, memory and neuroprotection.  This evidence 
provides great insight into the positive applications of lithium and how it may benefit 
post-menopausal women.  Though extrapolating results obtained from mice to human 
clinical applications is a giant leap, my study serves as a starting point to further 
investigate lithium’s potential benefits as an estrogen-mediated signaling modulator in a 
system deprived of this hormone.  
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CHAPTER IV 
Lithium: A Promising Alternative to Estrogen Replacement Therapy 
 
 
Abstract 
Estrogen replacement therapy (ERT) is a topic that engenders much debate since several 
studies contradict its efficacy as a palliative therapy for cognitive decline and 
neurodegenerative diseases.  Signaling transduction pathways can alter brain cell activity, 
survival, and morphology by facilitating transcription factor response element binding 
and protein production.  The steroidal hormone estrogen and the antidepressant drug 
lithium can interact through these signaling transduction pathways resulting in 
transcription factor activation.  The transcription factor cyclic adenosine monophosphate 
(cAMP) response element binding protein (CREB) is affected by both estrogen and 
lithium.  Genes involved in learning, memory and neuronal survival are regulated by 
CREB.  Activated of CREB is initiated via phosphorylation at serine 133 by protein 
kinases and, estrogen and its receptors (ER) facilitate this phosphorylation.  Glycogen 
synthase kinase-3beta (GSK-3β) attenuates CREB’s transcriptional properties via 
subsequent phosphorylation of its serine 129.  Lithium is known as a negative regulator 
of GSK-3β, thus facilitating CREB response element binding; interestingly, ER-α DNA-
binding properties are facilitated by GSK-3β.  In this chapter I include protein modeling 
depicting estrogen signaling and interactions of CREB/GSK-3β and ER-α/GSK-3β using 
I-TASSER and PatchDock web servers.  Understanding the molecular pathways of 
estrogen will assist identifying a palliative therapy for menopause-related dementia, and 
lithium may act as a selective estrogen-mediated signaling modulator. 
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4.1 Introduction  
Estrogen and lithium exert neuroprotective properties and may act as palliative 
treatments for neurodegeneration and cognitive decline [32, 65].  Alzheimer’s disease 
(AD) in post-menopausal women is related to estrogen deficiency, and estrogen 
replacement therapy (ERT) may benefit post-menopausal women in reducing the risk of 
developing AD [30].  Other studies, however, contradict these findings and suggest that 
hormone therapy does not improve cognitive decline during menopause, specifically 
episodic memory [43].  And, there is a high risk of developing breast cancer, marked by 
increased incidences of lobular carcinoma, in post-menopausal women undergoing ERT 
[76].  Furthermore, women suffering from depression during peri- and post-menopause 
are often prescribed lithium [13, 60].  Few studies focus on how estrogen and lithium 
may augment or counteract neuroprotective qualities, and studies demonstrating estrogen 
and lithium’s affect on learning and memory are conflicting.  Many underlying 
mechanisms still remain to be studied and ever increasing proteonomic- and genomic-
generated data suggest these as complex mechanisms.   
 
Using I-TASSER (Threading/ASSEmbly/Refinement) web server [104, 111, 112] 
I fabricated 3-D protein models (figures 1-6), but because of limited parent structures in 
the protein data bank (PDB), some models presented in this chapter display low 
complexity regions (e.g. indicated primarily by the lighter colored region in the 
background of figure 1; subsequent figures are not highlighted as such, though).  To 
choose the best model for this chapter, predicted models by I-TASSER were compared 
by superimposing crystallography structures from the PDB; superimposition was aided 
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by the structure based sequences alignment program (STRAP) and Pymol for visualizing 
the superimposition (see table 1 for accession number used to compare each predicted 
model).  For predicting transmembrane regions I used the TransMembrane prediction 
using Hidden Markov Models (TMHMM) web server to locate and specify 
transmembrane domains by representing a predicted hydrophobicity chart (specifically 
for figure 5A).  Literature mining and using the BLAST conserved domain web server 
(NCBI) assisted in locating specific amino acids specifying binding residues to produce 
the hypothetical protein-protein interactions in this chapter.  Figures depicting these 
protein-protein interactions were provided by the PatchDock web server [24, 94].   
 
Table 1. 
Predicted Protein NCBI Accession # Comparison Protein PDB Accession # 
    
CREB Isoform B NP_604391.1 
CREB Leucine 
Zipper 1dh3 
    
GSK-3β NP_002084.2 GSK-3β 1q4l 
    
ER-α NP_000116.2 ER-α 1l2i 
    
GPR30 NP_001091671.1 Rhodopsin 2J4Y 
 
Table 1. Specific amino acid sequences used to fabricate 3-D protein models.  These 
predicted models were superimposed with crystallography structures from PDB to justify 
predicted structures.  
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4.2 Neurosteroids and Estrogen Replacement Therapy  
 Menopause is marked by a massive drop in circulating estrogen.  The growing 
concern with estrogen deficiency is the increase incidence of neurodegenerative diseases 
and cognitive decline.  Circulating estrogen permeates the blood-brain barrier [61], and 
some speculate α-fetoprotein, a fetal plasma protein with a high affinity for estrogen, 
facilitates estrogen neuromechanisms [6, 68].  Estrogen is primarily produced by the 
gonads and the adrenal gland, but hormones, known as neurosteroids, are also produced 
in the brain [98].  Production of steroids by the gonads requires steroidogenic acute 
regulatory protein (StAR) to facilitate intermembrane passage of cholesterol, and StAR is 
ubiquitously expressed in the brain, but at low levels [98].  Women with a mutation in the 
StAR gene suffer from hormone deficiency leading to spontaneous puberty and an early 
onset of menopause [9].  Cholesterol is transported by StAR to the inner mitochondrial 
membrane where cytochrome P450 converts cholesterol into pregnenolone, the steroidal 
precursor [98].  Astrocytes are a source for steroidogenesis and glia-mediated steroidal 
production is linked to neuronal synaptic formation and to facilitating synaptic 
transmission [46].  Interestingly, StAR are expressed in glia and this co-localization is 
linked to glia-mediated steroidogenesis [98].  Little is known about how ERT affects 
StAR or how ERT affects the production of neurosteroids.  Should research be directed 
towards replacing estrogen in post-menopausal women, or geared towards enhancing 
neurosteroidogenisis and estrogen-mediated brain cell signaling pathways?   
 
The benefits of ERT are a controversial topic.  As mentioned, women undergoing 
ERT increase their risk of breast cancer [76], but there also lies a dichotomy with ERT in 
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relation to enhancing cognitive function and reducing neurodegenerative diseases.  For 
instance, Henderson et al. in 1994 concluded that ERT may reduce the risk of AD and 
cognitive decline during post-menopause, but in 2009 Henderson [43] is skeptical of ERT 
neuroprotective and neuroenhancing properties.  There is also a debate about a critical 
window hypothesis.  The hypothesis states that if ERT is initiated at a younger age, prior 
to menopause, it will improve cognitive functioning [96]; but Henderson considers these 
studies systematically bias [43].  Selective estrogen receptor modulators (SERMs) do 
provide an alternative to ERT, and studies show a decrease in breast cancer incidence and 
slows the progression of osteoporosis [51].  But SERMS use does not seem to improve 
cognitive functioning [75, 83].  If SERMs do not influence cognitive functioning an 
alternative treatment should be investigated, since estrogen does affect several brain cell 
signaling pathways involved in learning, memory and neuroprotection. 
 
4.3 Learning, Memory and Neuroprotection via Estrogen/Estrogen Receptor-mediated 
Pathways  
Estrogen facilitates brain cell signaling pathways that enhance synaptic plasticity 
[62], reduce glutamate excitotoxicity [44], increase neuroprotection of adult hippocampal 
cells [63], regulate neurotrophic factors [100], and facilitate transcription factor activation 
[67].  Learning and memory are products of gene regulation by transcription factors.  For 
example, cyclic adenosine monophosphate (cAMP) response element binding protein 
(CREB) regulates genes responsible for critical brain functions, including synaptic 
plasticity, learning, memory and neuroprotection [44, 53, 88, 102].  Activation of CREB 
is facilitated by estrogen [67] leading to the transcription of immediate early genes (e.g. 
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Ser133 
Ser129 
c-fos and c-jun), which in turn promotes phenotypical changes – e.g. synaptic plasticity 
[92].   In fear conditioning experiments mice exhibit an upregulation of immediate early 
genes in the hippocampus and this upregulation is mediated in the amygdala – the 
emotion processing center of the brain [47].  Mice with targeted mutations of CREB 
exhibit deficiencies in long-term memory storage, but not short-term memory storage 
[10].  Activation of CREB’s signaling pathway is initiated by adenylyl cyclase which 
catalyzes adenosine triphosphate (ATP) into cAMP that then activates cAMP dependent 
protein kinase (PKA) – PKA then phosphorylates CREB at its serine 133 site (figure 1) 
[12].  Estrogen and its receptors (ER) facilitate non-genomic molecular pathways by 
increasing CREB activity [67] and estrogen is known to increase cAMP levels by binding 
to G-protein coupled receptors (GPCR) that stimulate adenylyl cyclase activity [27].     
 
1. 
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Figure 1.  Phosphorylating CREB at its serine 133 (green) causes a conformational 
change in its leucine zipper region (cyan) causing CREB to dimerize with CREB binding 
protein.  This dimerization facilitates CREB response element binding. The 
conformational change that occurs, however, exposes CREB’s serine 129 region (red) 
allowing a subsequent phosphorylation attenuating CREB’s response element binding. 
(The yellow depicts the kinase inducible domain of CREB.  The light colored region 
indicates the low complexity region) 
 
2. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  GSK-3β. The darker magenta areas depict the protein kinase domains of GSK-
3β.  These regions possess ATP binding, catalytic, activation and substrate binding 
domains.  
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Glycogen synthase kinase-3beta (GSK-3β; figure 2) is a negative regulator of 
CREB via subsequent phosphorylation of CREB at serine 129 (figure 3) and this 
subsequent phosphorylation can only occur after the initial phosphorylation of serine 133 
[12, 35].  The serine 129 phosphorylation attenuates CREB transcriptional properties thus 
inhibiting CREB’s neuroprotective mechanisms [12, 35].  Classically, GSK-3β is well 
known for its inhibition of the transcription factor β-catenin in the Wnt signaling pathway 
[36].  β-catenin is necessary for activating genes responsible in general for embryonic 
development and more specifically for central nervous system development [36].  When 
bound by its ligand estrogen, ER-α causes an ephemeral inhibition of GSK-3β via 
phosphorylation of its serine residues [14].  ERs also act as ligand-activated transcription 
factors for the promoter region estrogen response element (ERE) [30, 64].   
 
To date, there are two known ERs: ERα and  ERβ [97].  In the nervous system, 
ERs are mainly located in the hypothalamus and amygdala (two areas responsible for the 
gonadal distribution of hormones), but are also located in regions of the cerebral cortex 
[70] and hippocampus [30, 97].  Hippocampal expression of ERs are noted in pyramidal 
cells and Solum and Handa (2002) measured brain derived neurotrophic factor (BDNF) 
mRNA expression in gonadectomized rats and found that BDNF mRNA decreased in the 
hippocampus of these gonadectomized rats, but was reversed with a single injection of 
estrogen.  This group also found that ER-α is co-localized with BDNF in pyramidal cells 
of the hippocampus [100], suggesting that ERs may play a role in memory and cognition 
[28, 67, 97].  By increasing the activation of second messenger signaling, such as calcium 
and cAMP that activate protein kinases [37], which  in turn activate CREB, estrogen 
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indirectly increases CREB activation [67].  Wu et al. (2005) proposed that estrogen/ER 
complex leads to neuroprotection by recruiting phosphatidylinositol-3 kinase (PI3K).  
The recruitment of PI3K by ERs increases intracellular calcium; calcium acts as a second 
messenger involved in several cell signaling pathways.  One specific downstream target 
of calcium is protein kinase C (PKC) that activates the Src/extracellular signal-regulated 
kinase (ERK) signaling pathway, leading to the transcription of B-cell 
lymphoma/leukeimia-2 (Bcl-2), via phosphorylated CREB [105].  PI3K also facilitates 
Bcl-2 anti-apoptotic activity by activating Akt which inhibits attenuating factors of Bcl-2 
[105].  Promotion of intracellular calcium levels via ER-mediated signaling is debatable 
since evidence show a rapid increase in intracellular calcium mediated by estrogen 
binding to GPR30, a serpentine transmembrane GPCR [7, 87].  Human keratinocytes 
treated with estrogen increases phosphorylated CREB levels and GPR30 anti-sense 
oligonucleotides attenuates this increase [52].  The difference in calcium influx mediated 
by ERs or GPR30 may be that ER-α has a binding affinity for a Src recruiter known as 
proline-, glutamic acid-, and leucine-rich protein-1 (PELP1) [11].  The recruitment of 
PELP1 binds Src and may lead to the PI3K/ERK/CREB pathway proposed by Wu et al. 
(2005).   
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3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Protein-protein interaction of CREB and GSK-3β.  Subsequent 
phosphorylation of CREB (cyan) at serine 129 (red) attenuates response element binding, 
thereby reducing cAMP-dependent transcription.  Subsequent phosphorylation is 
mediated by GSK-3β (magenta) and interaction is noted at lysine 205 (wheat) of GSK-
3β. 
 
 
Ser129 
Lys205 
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The dominant form of estrogen, 17β-estradiol (E2), has an affinity for ER-α 
(figure 4) leading to transcription factor activation, but E2 can mediate protein signaling 
pathways through ERs and non-ERs.   As mentioned, PELP1 is a co-regulator of ER-α 
and this interaction leads to Akt/PI3K signaling pathways [11] – a pathway facilitated by 
lithium involving GSK-3β inhibition [20].  But E2 also binds to the GPCR, GPR30 a 
serpentine receptor.  Expression of GPR30 is noted on the plasma membrane but it is also 
recognized in the endoplasmic reticulum [89].  The rhodopsin family are GPCRs 
possessing the seven transmembrane α-helices and GPR30 share these conserved 
domains (figure 5A).  Ligand binding of E2 activates GPR30 (figure 5B) and this binding 
facilitates cAMP production [89].  Figure 5B depicts ligand binding of E2 to the outer 
and inner membrane – these are hypothetical binding sites using PatchDock web server.   
 
Response element binding by ER-α relies on GSK-3β phosphorylation and this 
phosphorylation is inhibited in the presence of lithium.  Medunjanin et al. [69] suggested 
that when GSK-3β is phosphorylated at serine 9 it will disassociate itself from ER-α, 
allowing ER-α to migrate to the nucleus for a subsequent phosphorylation by GSK-3β – 
consequently activating ER-α transcriptional properties (figure 6).  Palindromic DNA 
sequences are recognized by ER-α, and expressed in promoter regions for NMDA 
receptor subunits [103]; thus, estrogen has a direct genomic role in NMDA receptor 
subunit expression.  
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4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  ER-α.  This figure depicts ER-α bound by E2 (blue) at arginine 394 within the 
ligand binding domain (foreground; orange).  The ligand binding domain also contains 
the co-activator recognition site and dimer interface.  Domains are conserved in ER-α 
classifying it as part of the ER family (background; light orange) and as a transcription 
factor due to its zinc finger domain (cyan).   
Arg394 
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Figure 5A-5B.  GPR30.  This superimposition depicts GPR30 (green) sharing similar 
structure to rhodopsin (red) (A).  GPR30 express seven α-helices transmembrane 
domains (green) and putative binding of E2 (blue) is shown on the outer membrane 
(cyan) at phenylalanine 298 and glutamine 54, and inner membrane (cyan)  at arginine 
248 (B).   
 
 
6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  Protein-protein interaction of ER-α and GSK-3β.  Once bound by estrogen 
(blue), ER-α (orange) mediates cell signaling pathways or acts as a transcription factor.  
Response element binding of ER-α is facilitated by GSK-3β (magenta) phosphorylation.  
This figure depicts binding of ER-α at serine 104 (green) by lysine 205 (wheat) of GSK-
Lys205 
Ser104 
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3β.  The non-bound residues in green (ER-α) and wheat (GSK-3β) are the binding sites 
described by Medunjanin et al. [69] and Ilouz et al. [48], respectively. The GSK-3β 
amino acid residue responsible for phosphorylating ER-α depicted in this figure is the 
same residue that phosphorylates CREB at serine 129 (figure 3). 
 
 
4.4 Lithium  
To elucidate lithium’s prophylactic properties for bipolar disorder, investigators 
postulated mechanisms involving inositol depletion [39] and GSK-3β inhibition [33].  
Inositol depletion hypothesis states that lithium inhibits inositol monophosphatase thus 
depleting the amount of free inositol [39].  Inositol signaling ultimately releases calcium 
stored in the endoplasmic reticulum affecting several signaling pathways.  Inositol 
signaling via glutamate receptor increases protein kinase activity, transcription factor 
activation [78] and is highly involved in synaptic plasticity [26].  Using Dictyostelium 
and human neutrophil cell line (HL60), King et al. [55] systematically investigated the 
hypothesis that lithium suppresses inositol-mediated signaling.  This group showed that 
lithium reduces phosphoinositide and this reduction is reversed by over expressing 
inositol monophosphatase [55].  Two inositol monophosphatases have been identified 
(IMPA1 and IMPA2) and IMPA2 is highly associated not only with bipolar disorder, but 
schizophrenia as well [108].  A high concentration of magnesium and a high pH are 
required for IMPA2 compared with IMPA1 [81].  Ohnishi et al. (2007) showed that 
lithium also inhibits IMPA2 and this inhibition hinders magnesium concentrations.  
Bipolar patients treated with lithium show a decrease in inositol monophosphatase 
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activity in red blood cells compared with non-treated bipolar patients [58], but 
cerebrospinal fluid from lithium-treated patients suffering from bipolar or schizophrenia 
show an increase in inositol monophosphatase activity [5]. 
 
For over a decade though, studies demonstrate lithium specifically inhibiting 
GSK-3β [25, 56] and this inhibition is associated with reducing apoptotic activity [45], 
enhancing neurotrophic factors [4], and facilitating CREB DNA binding [35, 82].  
Interestingly, learning and memory centers of the brain are influenced by lithium, since 
lithium increases performance in hippocampal-dependent spatial memory tasks [95].  An 
extensive study using GSK-3β heterozygous knockout mice analyzed behavioral 
parameters from apomorphine-induced stereotypic behavior to startle response and found 
no distinct difference in behavior [8].  This may lead one to postulate that lithium may 
affect learning and memory through GSK-3β independent mechanisms.  
 
Though the mechanism remains elusive, GSK-3β inhibition by lithium is 
described as acting through both direct and indirect mechanisms.  Indirectly, lithium 
inhibits GSK-3β by activating protein kinases that phosphorylate the kinase at its 
inhibitory serine 9 residue or by inactivating phosphatases that remove this phosphate 
group [50].  Enzymatic activity is highly dependent on magnesium and lithium directly 
inhibits GSK-3β by acting as a competitive inhibitor of magnesium; magnesium being a 
cofactor for ATP in GSK-3β activation [91].  Thus, GSK-3β inhibition by lithium 
protects/rescues the brain from apoptotic cell death; and neural dysfunction results from 
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the failure to completely inhibit GSK-3β [35].  In addition, lithium-treated rats show an 
upregulation of Bcl-2 in layers II and III of the frontal cortex, dentate gyrus and striatum 
[65].  I can reasonable assume that long-term administration of lithium could provide 
neuroprotection by increasing neuronal survival.  Neuroprotective qualities of lithium are 
also associated with increasing BDNF expression and facilitating BDNF signaling via 
tyrosine kinase receptor.  Rat cortical neurons treated with lithium or BDNF had similar 
neuroprotective qualities; however, lithium required a chronic treatment (6 days) as 
opposed to an acute action by BDNF (1 day) [42].  These neuroprotective qualities are 
attenuated by BDNF neutralizing antibodies and specific inhibitors for tyrosine kinase 
[42].  The signaling cascade of BDNF/tyrosine kinase receptor also activates PI3K/Akt 
signaling pathways, ultimately leading to neuronal survival and increasing Bcl-2 
expression [85].  Neuroprotection of cerebellar granule neurons by lithium via tyrosine 
kinase activity is also documented, since this neuroprotection is abolished with tyrosine 
kinase inhibitors [34]. 
 
Phencyclidine (PCP), also known as angel dust, is an NMDA receptor antagonist 
and its actions result in schizophrenic-like behavior [16]; clinically, lithium is also 
prescribed for schizophrenia [17].  PCP inhibits PI3K/Akt and ERK signaling pathways, 
and PCP activates GSK-3β by facilitating the dephosphorylation of its serine 9 residue, 
however, lithium reverses PI3K /Akt and ERK inhibition and GSK-3β activation [106].  
Lithium indirectly effects NMDA receptor signaling pathway by reducing 
phosphorylation and activation of Src-tyrosine kinase activity.  Furthermore, 
phosphorylation of NR2 subunits of NMDA receptor by Src tyrosine kinases is essential 
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for the receptor’s signal transduction activity and Hashimoto et al. [40] demonstrates that 
phosphorylated levels of Src tyrosine kinase decreases in a time-dependent fashion when 
treated with lithium.  Although NMDA receptor is highly involved in learning and 
memory it also mediates glutamate excitotoxicity, and this mediation reduces 
phosphorylated CREB levels [59].  Diminished phosphorylated CREB is regulated by 
protein phosphatase 1 [59], a factor involved in GSK-3β activation [110].  When 
Kopnisky et al. [59] chronically treated neuronal cultures with lithium, protein 
phosphatase 1 activity decreased, thereby increasing phosphorylated CREB levels; 
lithium also increased ERK signaling pathway.  Post-synaptic glutamate receptors, like 
NMDA receptor, facilitates synaptic connectivity and conductivity, and lithium enhances 
this facilitation; interestingly, enhanced synaptic plasticity is correlated with 
phosphoinositide depletion and not GSK-3β inhibition [54].  Lithium is double-edged in 
interacting with glutamate receptors, but only to balance the properties of glutamate 
receptor signaling pathways.  This means that lithium attenuates glutamate receptor-
mediated excitoxicity [41], but also facilitates, maintains and strengthens glutamate 
receptor-mediated synaptic connectivity and communication [54].  If lithium is a 
competitive inhibitor of magnesium [91] and glutamate receptor channels bind 
magnesium [18], could lithium then directly affect glutamate receptor?  Would lithium’s 
direct interaction lead to glutamate receptor inhibition or facilitate its activity, or both?   
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4.5 Estrogen and Lithium; or, Lithium as a Selective Estrogen-Mediated Signaling 
Modulator  
To date, few studies focus on the neurobiological affects of combined estrogen 
and lithium.  Several studies employ lithium in taste aversion task and in inducing 
seizures.  Seizures are induced by injecting lithium in specific stereotactic brain regions 
causing status epilepticus (e.g. seizures) to occur.  Estrogen protects rat hippocampus 
from these induced seizures; however, this protection is gender specific [29].  Lithium 
permeates cells through sodium-potassium ATPase pumps and this permeation is 
dependent on sodium-lithium counterflow and exchange [84], which increases 
cytoplasmic pH levels thus altering cell activity [57].  Sodium-lithium counterflow is 
increased by long-term use of oral contraceptives [2]; interestingly, lithium does not alter 
ER-α expression in murine uterine tissue, but ovariectomized mice treated with 
combined estrogen and lithium reduces uterine ER-α expression [38].   
 
Taste aversion tasks use lithium to cause an adverse reaction to a rewarding 
stimulus (e.g., sucrose water) and studies show that estrogen hinders ovariectomized rats 
ability to detect dilute sucrose solutions [19].  Estrogen accelerates extinction of 
conditioned taste aversion behavior, but this is dependent on when estrogen was 
administered (e.g., before or during extinction) [109].  Combined lithium and estrogen 
decreases inflammation of stomach lining, but individual treatment does not affect gastric 
erosions [1].  Both estrogen and lithium affect enkephalins, a regulator of nociceptic 
responses (e.g., noxious stimuli).  In analyzing rat anterior pituitary, Yoshikawa and 
Hong (1983), found that enkephalin expression is sex dependent – males express higher 
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levels than females.  Administering estrogen to male rats decreases enkephalins, but 
testosterone increases enkephalins in the anterior pituitary of female rats [107].  Rats 
were also administered lithium and Yoshikawa and Hong [107] noted a decrease in 
enkephalins of the anterior pituitary for both male and female rats.  This led them to 
conclude that the enkephalin system is mediated by the dopamine pathway [107].  
Parkinson disease and clinical disorders, such as bipolar disorder, are highly associated 
with the dopamine pathway, a pathway affected by both estrogen and lithium [74, 99].  
 
An increase in intracellular sodium concentration mediated by dopaminergic 
pathways is a characteristic of bipolar disorder and lithium normalizes this increase [90].  
Studies show that combined estrogen and lithium alter serotonin and dopamine 
metabolites.  Estrogen does not change serotonin levels, dopamine or dopamine 
metabolites in the frontal cortex of ovariectomized rats, but when estrogen is combined 
with lithium, dopamine drastically decreases [73]. This decrease is associated with higher 
serotonin levels and dopamine metabolites [73].  Apomorphine is a dopaminergic agonist 
that increases stereotyped-behavior (e.g., Parkinsonian symptoms) as noted in 
ovariectomized rats after discontinuing chronic treatment of estrogen; but this increase in 
stereotyped-behavior is diminished with lithium [23].    
 
Lithium does not affect basal levels of cAMP, but when stimulated by dopamine, 
lithium inhibits adenylyl cyclase activity and this is shown in vitro and in vivo [72].  
Lithium’s inhibition of dopamine-stimulated adenylyl cyclase is not through GPCR 
signaling pathway, as indicated using the dopamine receptor agonist, quinpirole [72]; 
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interestingly, GTP hydrolysis is decreased by lithium, but not when stimulated by 
catecholamines  (i.e. dopamine and epinephrine) [79].  There instead seems to be a direct 
inhibition of adenylyl cyclase by lithium but only when adenylyl cyclase is activated 
[66].  Studies show that lithium hinders hormone and dopamine-stimulated adenylyl 
cyclase activity in rat cerebral cortex and this group concluded that lithium is causing this 
hindrance via competitive inhibition (e.g. magnesium) [77].  Will lithium inhibit GPR30-
stimulated adenylyl cyclase activity? 
 
There is a correlation of adenylyl cyclase activity and progression of AD.  Post-
mortem hippocampi of AD patients showed a decrease in adenylyl cyclase activity that 
resulted from a hindrance in the catalytic domain [80].  Progression of AD is associated 
with producing excessive amounts of the insoluble amyloid beta – a proteolytic product 
of amyloid precursor protein (APP) cleaved by β-secretase [31].  Cleavage of APP by α-
secretase can produce a soluble product rendering it benign.  Estrogen does increase α-
secretase mediated cleavage and lithium mimics this increase – potentially through GSK-
3β inhibition [32].  Post-mortem AD brains also show a decrease in NMDA receptor 
subunit mRNA for NR1 and NR2B in the hippocampal formation during advancement of 
the disease [71].    
 
Estrogen facilitates calcium influx that promotes factors involved in neuronal 
survival and synaptic plasticity [93].  Neurodegenerative diseases, like AD, are marked 
by increased excitotoxicity, because of high intracellular calcium levels in brain cells 
[22], and postmenopausal women suffer from AD [43].  Should women with a higher 
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likelihood of progressive neurodegenerative functions be prescribed ERT?  Or should 
postmenopausal therapy be directed towards modulating estrogen brain cell signaling 
pathways?  Lithium is extremely toxic if serum levels exceed therapeutic range (0.6 - 1.4 
mM) as shown by treating rats for up to 28 days and lithium increases estrogen levels via 
antagonizing ERs [3].  Recent studies, however, indicate that lithium facilitates 
proliferation of epithelial cells and these cells show an increased ER expression [86]; 
lithium also increases estrogen production [15].  Although lithium is classically used to 
treat bipolar syndrome it has an incredible propensity for stabilizing molecular 
mechanisms.  Jope (1999) proposes a bimodal model for lithium, since lithium regulates 
positive and negative cell signaling mechanisms resulting in raising basal activities and 
reducing maximal activities or by increasing basal levels and reducing maximal levels of 
cell signaling mechanisms [49].  Lithium’s bimodal mechanism may facilitate ER-
mediated brain cell signaling during post-menopause by increasing the activity level in a 
system deprived of its basal level of estrogen.  
 
4.6 Closing Remarks  
 Although ERT is used to treat post-menopausal women, studies recognize that 
ERT does not alleviate cognitive decline or the advancement of neurodegenerative 
diseases.  Therapies should be directed towards enhancing estrogen-mediated 
neuromechanisms instead of supplementing the system with estrogen (or hormones in 
general).  SERMs do provide an alternative to ERT, and, although advancement of 
neurodegenerative diseases are attenuated [21], SERMs do not improve cognitive 
functioning [75, 83].  Over 60 years ago John Frederick Joseph Cade, an Australian 
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psychiatrist, first recognized the calming effects of lithium on small animals and on 
himself (Cade, 1949).  Since then lithium has been used to treat bipolar disorder and over 
a decade has past since the molecular mechanisms for lithium began to be recognized 
[56].  These molecular implications have expanded lithium’s profile as a cognitive 
enhancer and an anti-neurodegenerative agent [65].   
 
As discussed in this chapter, both estrogen and lithium facilitate a plethora of 
signaling transduction pathways resulting in anti-apoptosis, protein expression, learning 
and memory.  Figure 7 depicts the multitude of pathways affected by estrogen and 
suggests ways in which lithium interacts with these signaling transduction pathways.  I 
noted in chapters one and two, that the combined effects of E2 and LiCl (E2/LiCl) 
reduced NMDAR subunit NR1 gene expression and increased glutamate excitotoxicity in 
embryonic mouse hippocampal and cortical primary mixed cultures, predominated by 
glia [101].  These results were accompanied by noting that combined E2/LiCl also 
increased BDNF and ER-α genetic expression (chapter two).  I also showed that lithium 
treatment alone can increase episodic memory and that this coincides with enhanced 
expression of markers involved in learning, memory and neuroprotection (chapter three).  
The research presented in this dissertation is still in its infancy and care must be taken in 
considering these results applicability towards any clinical implications; but I believe to 
further study the involvement of antidepressants and hormones will provide a better 
treatment regime for post-menopausal women.  
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7. 
 
Figure 7.  A post-synaptic cell signaling schematic of the mechanism described in this 
chapter.  ATP, adenosine triphosphate; CREB, cyclic adenosine monophosphate (cAMP) 
response element binding protein; ER, estrogen receptor; GPR30, G–protein coupled 
receptor 30; GSK-3β, glycogen synthase-3beta; NMDAR, N-methyl-D-aspartate; PKA, 
cAMP dependent protein kinase.  (       , putative interaction;        , activating/interacting;  
     , inhibitory) 
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